1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−00−5 : 1−Chloro−4−nitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−00−5 : 1−Chloro−4−nitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−01−6 : 4−Nitroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−01−6 : 4−Nitroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−02−7 : 4−Nitrophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−02−7 : 4−Nitrophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10016−20−3 : alpha−Cyclodextrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10016−20−3 : alpha−Cyclodextrin

Agonist: 0 Antagonist: 0.00022

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−21−0 : Terephthalic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−21−0 : Terephthalic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10025−74−8 : Dysprosium(III) chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10025−74−8 : Dysprosium(III) chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−37−8 : N,N−Diethylethanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−37−8 : N,N−Diethylethanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10042−59−8 : 2−Propyl−1−heptanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10042−59−8 : 2−Propyl−1−heptanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10043−35−3 : Boric acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10043−35−3 : Boric acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−51−6 : Benzyl alcohol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−51−6 : Benzyl alcohol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−54−9 : 3−Pyridinecarbonitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−54−9 : 3−Pyridinecarbonitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−64−1 : Cyclohexanone oxime

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−64−1 : Cyclohexanone oxime

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1007−28−9 : Deisopropylatrazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1007−28−9 : Deisopropylatrazine

Agonist: 0.0035 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10081−67−1 : 4−(2−Phenylpropan−2−yl)−N−[4−(2−phenylpropan−2−yl)phenyl]aniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10081−67−1 : 4−(2−Phenylpropan−2−yl)−N−[4−(2−phenylpropan−2−yl)phenyl]aniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1008−72−6 : Sodium 2−formylbenzenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1008−72−6 : Sodium 2−formylbenzenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10094−34−5 : 1,1−Dimethyl−2−phenylethyl butanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10094−34−5 : 1,1−Dimethyl−2−phenylethyl butanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−97−0 : Methenamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 100−97−0 : Methenamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−02−0 : Triphenyl phosphite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−02−0 : Triphenyl phosphite

Agonist: 0.0041 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−05−3 : Anilazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−05−3 : Anilazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−10−0 : Cloprop

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−10−0 : Cloprop

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−20−2 : Triclocarban

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−20−2 : Triclocarban

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−21−3 : Chlorpropham

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−21−3 : Chlorpropham

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−37−1 : 2,4,6−Tris(allyloxy)−1,3,5−triazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−37−1 : 2,4,6−Tris(allyloxy)−1,3,5−triazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−42−8 : Fenuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−42−8 : Fenuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101463−69−8 : Flufenoxuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101463−69−8 : Flufenoxuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−54−2 : N−Phenyl−1,4−benzenediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−54−2 : N−Phenyl−1,4−benzenediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−55−3 : p−Bromodiphenyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−55−3 : p−Bromodiphenyl ether

Agonist: 0.016 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−61−1 : 4,4'−Methylenebis(N,N−dimethylaniline)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−61−1 : 4,4'−Methylenebis(N,N−dimethylaniline)

Agonist: 0.025 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10161−33−8 : 17beta−Trenbolone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10161−33−8 : 17beta−Trenbolone

Agonist: 0.6 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−77−9 : 4,4'−Methylenedianiline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−77−9 : 4,4'−Methylenedianiline

Agonist: 0.0081 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−80−4 : 4,4'−Oxydianiline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−80−4 : 4,4'−Oxydianiline

Agonist: 0.012 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−81−5 : Diphenylmethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−81−5 : Diphenylmethane

Agonist: 0.025 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−83−7 : Dicyclohexylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−83−7 : Dicyclohexylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−84−8 : Diphenyl oxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−84−8 : Diphenyl oxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−86−0 : 2−Benzylideneoctanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 101−86−0 : 2−Benzylideneoctanal

Agonist: 0.0077 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−06−7 : 1,3−Diphenylguanidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−06−7 : 1,3−Diphenylguanidine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10222−01−2 : 2,2−Dibromo−3−nitrilopropionamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10222−01−2 : 2,2−Dibromo−3−nitrilopropionamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−27−2 : N−Ethyl−3−methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−27−2 : N−Ethyl−3−methylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1024−57−3 : Heptachlor epoxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1024−57−3 : Heptachlor epoxide

Agonist: 0.014 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−60−3 : N,N,N',N'−Tetrakis(2−Hydroxypropyl)ethylenediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−60−3 : N,N,N',N'−Tetrakis(2−Hydroxypropyl)ethylenediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10265−92−6 : Methamidophos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10265−92−6 : Methamidophos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102676−31−3 : Fadrozole hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102676−31−3 : Fadrozole hydrochloride

Agonist: 0.075 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−71−6 : Triethanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−71−6 : Triethanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−76−1 : Triacetin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−76−1 : Triacetin

Agonist: 0.014 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−82−9 : Tributylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 102−82−9 : Tributylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103055−07−8 : Lufenuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103055−07−8 : Lufenuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−09−3 : 2−Ethylhexyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−09−3 : 2−Ethylhexyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1031−07−8 : Endosulfan sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1031−07−8 : Endosulfan sulfate

Agonist: 0 Antagonist: 0.0061

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−11−7 : 2−Ethylhexyl acrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−11−7 : 2−Ethylhexyl acrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−23−1 : Di(2−ethylhexyl) adipate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−23−1 : Di(2−ethylhexyl) adipate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−24−2 : Bis(2−ethylhexyl) nonanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−24−2 : Bis(2−ethylhexyl) nonanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−33−3 : Azobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−33−3 : Azobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−34−4 : 4,4'−Dithiodimorpholine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−34−4 : 4,4'−Dithiodimorpholine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103361−09−7 : Flumioxazin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103361−09−7 : Flumioxazin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1034−01−1 : Octyl gallate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1034−01−1 : Octyl gallate

Agonist: 0.044 Antagonist: 0.1

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−41−3 : Benzyl cinnamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−41−3 : Benzyl cinnamate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−65−1 : Propylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−65−1 : Propylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−69−5 : N−Ethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−69−5 : N−Ethylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−76−4 : 1−Piperazineethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−76−4 : 1−Piperazineethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−90−2 : Acetaminophen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 103−90−2 : Acetaminophen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104098−48−8 : Imazapic

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104098−48−8 : Imazapic

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−13−2 : 4−Butylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−13−2 : 4−Butylaniline

Agonist: 0.008 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104206−82−8 : Mesotrione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104206−82−8 : Mesotrione

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−40−5 : 4−Nonylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−40−5 : 4−Nonylphenol

Agonist: 0.11 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−43−8 : 4−Dodecylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−43−8 : 4−Dodecylphenol

Agonist: 0.56 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−45−0 : 4−Propylanisole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−45−0 : 4−Propylanisole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−51−8 : Butylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−51−8 : Butylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10453−86−8 : Resmethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10453−86−8 : Resmethrin

Agonist: 0.0077 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−54−1 : 3−Phenyl−2−propen−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−54−1 : 3−Phenyl−2−propen−1−ol

Agonist: 0.0064 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−61−0 : gamma−Nonanolactone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−61−0 : gamma−Nonanolactone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−66−5 : 1,2−Diphenoxyethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−66−5 : 1,2−Diphenoxyethane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−67−6 : 5−Heptyldihydro−2(3H)−furanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−67−6 : 5−Heptyldihydro−2(3H)−furanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−76−7 : 2−Ethyl−1−hexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104−76−7 : 2−Ethyl−1−hexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104795−68−8 : CI−959

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 104795−68−8 : CI−959

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−21−5 : 1,4−Heptanolide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−21−5 : 1,4−Heptanolide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−37−3 : Ethyl propionate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−37−3 : Ethyl propionate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10540−29−1 : Tamoxifen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10540−29−1 : Tamoxifen

Agonist: 0.042 Antagonist: 0.69

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105512−06−9 : Clodinafop−propargyl mixt.

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105512−06−9 : Clodinafop−propargyl mixt.

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−53−3 : Diethyl propanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−53−3 : Diethyl propanedioate

Agonist: 0.0031 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−54−4 : Ethyl butyrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−54−4 : Ethyl butyrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−55−5 : N,N'−Diethylthiourea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−55−5 : N,N'−Diethylthiourea

Agonist: 0.019 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−60−2 : Caprolactam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−60−2 : Caprolactam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105624−86−0 : 5HPP−33

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105624−86−0 : 5HPP−33

Agonist: 0.58 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−67−9 : 2,4−Dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−67−9 : 2,4−Dimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−87−3 : Geranyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−87−3 : Geranyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−99−7 : Dibutyl hexanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 105−99−7 : Dibutyl hexanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10605−21−7 : Carbendazim

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 10605−21−7 : Carbendazim

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1061517−62−1 : PharmaGSID_47337

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1061517−62−1 : PharmaGSID_47337

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−22−9 : Citronellol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−22−9 : Citronellol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−23−0 : Citronellal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−23−0 : Citronellal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−24−1 : Geraniol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−24−1 : Geraniol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−25−2 : (2Z)−3,7−Dimethylocta−2,6−dien−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−25−2 : (2Z)−3,7−Dimethylocta−2,6−dien−1−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−27−4 : Isopentyl butyrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−27−4 : Isopentyl butyrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−30−9 : Ethyl heptanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−30−9 : Ethyl heptanoate

Agonist: 0.015 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−43−4 : 4−Chlorotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−43−4 : 4−Chlorotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−44−5 : p−Cresol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−44−5 : p−Cresol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−45−6 : 4−Thiocresol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−45−6 : 4−Thiocresol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−46−7 : 1,4−Dichlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−46−7 : 1,4−Dichlorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−47−8 : 4−Chloroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−47−8 : 4−Chloroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−48−9 : 4−Chlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−48−9 : 4−Chlorophenol

Agonist: 0.05 Antagonist: 0.019

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−49−0 : 4−Methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−49−0 : 4−Methylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−50−3 : 1,4−Benzenediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−50−3 : 1,4−Benzenediamine

Agonist: 0.02 Antagonist: 0.025

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−65−0 : Dimethyl succinate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−65−0 : Dimethyl succinate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−68−3 : 3−Octanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−68−3 : 3−Octanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1067−25−0 : Trimethoxypropylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1067−25−0 : Trimethoxypropylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1067−53−4 : Tris(2−methoxyethoxy)vinylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1067−53−4 : Tris(2−methoxyethoxy)vinylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−87−6 : 4−Vinyl−1−cyclohexene dioxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−87−6 : 4−Vinyl−1−cyclohexene dioxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1068967−96−3 : SAR102608

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1068967−96−3 : SAR102608

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−93−4 : 1,2−Dibromoethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 106−93−4 : 1,2−Dibromoethane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−07−3 : 2−Chloroethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−07−3 : 2−Chloroethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−13−1 : Acrylonitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−13−1 : Acrylonitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−18−6 : Allyl alcohol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−18−6 : Allyl alcohol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−20−0 : Chloroacetaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−20−0 : Chloroacetaldehyde

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−21−1 : Ethylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−21−1 : Ethylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1072−15−7 : Sulfuric acid, monononyl ester, sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1072−15−7 : Sulfuric acid, monononyl ester, sodium salt

Agonist: 0.091 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−30−2 : Chloromethyl methyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−30−2 : Chloromethyl methyl ether

Agonist: 0.02 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−41−5 : 2−Methyl−2,4−pentanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−41−5 : 2−Methyl−2,4−pentanediol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−46−0 : Hexamethyldisiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−46−0 : Hexamethyldisiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−51−7 : Octamethyltrisiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−51−7 : Octamethyltrisiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107534−96−3 : Tebuconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107534−96−3 : Tebuconazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−54−0 : 3,5−Dimethyl−1−hexyn−3−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−54−0 : 3,5−Dimethyl−1−hexyn−3−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1076−97−7 : 1,4−Cyclohexanedicarboxylic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1076−97−7 : 1,4−Cyclohexanedicarboxylic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−75−5 : 7−Hydroxy−3,7−dimethyloctanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−75−5 : 7−Hydroxy−3,7−dimethyloctanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−87−9 : 2−Pentanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−87−9 : 2−Pentanone

Agonist: 0.0029 Antagonist: 0.0076

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−88−0 : 1,3−Butanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−88−0 : 1,3−Butanediol

Agonist: 0.00018 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−92−6 : Butanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−92−6 : Butanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−98−2 : 1−Methoxy−2−propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 107−98−2 : 1−Methoxy−2−propanol

Agonist: 0.015 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−01−0 : Dimethylaminoethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−01−0 : Dimethylaminoethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−11−2 : 4−Methyl−2−pentanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−11−2 : 4−Methyl−2−pentanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−21−4 : Isopropyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−21−4 : Isopropyl acetate

Agonist: 0.024 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−32−7 : Propylene carbonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−32−7 : Propylene carbonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−38−3 : 1,3−Dimethylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−38−3 : 1,3−Dimethylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−39−4 : m−Cresol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−39−4 : m−Cresol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108419−33−6 : Acetic acid, C8−10−branched alkyl esters, C9−rich

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108419−33−6 : Acetic acid, C8−10−branched alkyl esters, C9−rich

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−44−1 : 3−Methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−44−1 : 3−Methylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−45−2 : 1,3−Benzenediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−45−2 : 1,3−Benzenediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−46−3 : Resorcinol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−46−3 : Resorcinol

Agonist: 0.0057 Antagonist: 0.014

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1085−12−7 : Heptylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1085−12−7 : Heptylparaben

Agonist: 0.38 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−59−8 : Dimethyl malonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−59−8 : Dimethyl malonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−67−8 : 1,3,5−Trimethylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−67−8 : 1,3,5−Trimethylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−68−9 : 3,5−Dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−68−9 : 3,5−Dimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−77−0 : 2,4,6−Trichloro−s−triazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−77−0 : 2,4,6−Trichloro−s−triazine

Agonist: 0.0051 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−80−5 : Cyanuric acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−80−5 : Cyanuric acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−83−8 : Diisobutyl ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−83−8 : Diisobutyl ketone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−91−8 : Cyclohexylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−91−8 : Cyclohexylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−93−0 : Cyclohexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−93−0 : Cyclohexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−94−1 : Cyclohexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−94−1 : Cyclohexanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−95−2 : Phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−95−2 : Phenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−98−5 : Benzenethiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 108−98−5 : Benzenethiol

Agonist: 0.008 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−02−4 : 4−Methylmorpholine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−02−4 : 4−Methylmorpholine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−43−3 : Dibutyl decanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−43−3 : Dibutyl decanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−46−6 : N,N'−Dibutylthiourea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−46−6 : N,N'−Dibutylthiourea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−52−4 : Pentanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−52−4 : Pentanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−55−7 : 3−(Dimethylamino)propylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−55−7 : 3−(Dimethylamino)propylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1095−90−5 : Methadone hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1095−90−5 : Methadone hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−77−3 : Propanedinitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−77−3 : Propanedinitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−86−4 : 2−Methoxyethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 109−86−4 : 2−Methoxyethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−05−4 : Di−tert−butyl peroxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−05−4 : Di−tert−butyl peroxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−12−3 : 5−Methyl−2−hexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−12−3 : 5−Methyl−2−hexanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−15−6 : Butanedioic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−15−6 : Butanedioic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−16−7 : Maleic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−16−7 : Maleic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−17−8 : Fumaric acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−17−8 : Fumaric acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110235−47−7 : Mepanipyrim

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110235−47−7 : Mepanipyrim

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−25−8 : Oleyl sarcosine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−25−8 : Oleyl sarcosine

Agonist: 0 Antagonist: 0.017

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−26−9 : N,N'−Methylenebisacrylamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−26−9 : N,N'−Methylenebisacrylamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−27−0 : Isopropyl tetradecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−27−0 : Isopropyl tetradecanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−33−8 : Dihexyl hexanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−33−8 : Dihexyl hexanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−42−9 : Methyl decanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−42−9 : Methyl decanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−43−0 : 2−Heptanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−43−0 : 2−Heptanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−44−1 : Sorbic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−44−1 : Sorbic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110488−70−5 : Dimethomorph

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110488−70−5 : Dimethomorph

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−62−3 : Pentanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−62−3 : Pentanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−63−4 : 1,4−Butanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−63−4 : 1,4−Butanediol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−65−6 : 2−Butyne−1,4−diol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−65−6 : 2−Butyne−1,4−diol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−69−0 : Butanal oxime

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−69−0 : Butanal oxime

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−73−6 : 2−(Ethylamino)ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−73−6 : 2−(Ethylamino)ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−80−5 : 2−Ethoxyethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−80−5 : 2−Ethoxyethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−85−0 : Piperazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−85−0 : Piperazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−87−2 : 3,4−Dihydro−2H−pyran

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−87−2 : 3,4−Dihydro−2H−pyran

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−91−8 : Morpholine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−91−8 : Morpholine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−97−4 : Diisopropanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 110−97−4 : Diisopropanolamine

Agonist: 0.088 Antagonist: 0.0027

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 11099−07−3 : Glyceryl stearates

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 11099−07−3 : Glyceryl stearates

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−11−5 : Methyl octanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−11−5 : Methyl octanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−14−8 : Heptanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−14−8 : Heptanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−15−9 : 2−Ethoxyethyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−15−9 : 2−Ethoxyethyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1111−78−0 : Ammonium carbamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1111−78−0 : Ammonium carbamate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−20−6 : Decanedioic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−20−6 : Decanedioic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−21−7 : Triethylene glycol diacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−21−7 : Triethylene glycol diacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1112−39−6 : Dimethoxydimethylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1112−39−6 : Dimethoxydimethylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−27−3 : 1−Hexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−27−3 : 1−Hexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−30−8 : Glutaraldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−30−8 : Glutaraldehyde

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−40−0 : Diethylenetriamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−40−0 : Diethylenetriamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−42−2 : Diethanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−42−2 : Diethanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−44−4 : Bis(2−chloroethyl) ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−44−4 : Bis(2−chloroethyl) ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−46−6 : Diethylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−46−6 : Diethylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1114−71−2 : Pebulate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1114−71−2 : Pebulate

Agonist: 0.0041 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−49−9 : Hexamethyleneimine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−49−9 : Hexamethyleneimine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−55−7 : 1,2−Ethanediol diacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−55−7 : 1,2−Ethanediol diacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−62−6 : Ethyl oleate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−62−6 : Ethyl oleate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−69−3 : Hexanedinitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−69−3 : Hexanedinitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−70−6 : 1−Heptanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−70−6 : 1−Heptanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−71−7 : Heptanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−71−7 : Heptanal

Agonist: 0.03 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−76−2 : 2−Butoxyethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−76−2 : 2−Butoxyethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−77−3 : Diethylene glycol monomethyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−77−3 : Diethylene glycol monomethyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111812−58−9 : Fenpyroximate (Z,E)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111812−58−9 : Fenpyroximate (Z,E)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−82−0 : Methyl dodecanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−82−0 : Methyl dodecanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−84−2 : Nonane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−84−2 : Nonane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1118−46−3 : Butyltin trichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1118−46−3 : Butyltin trichloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−87−5 : 1−Octanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−87−5 : 1−Octanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1118−92−9 : N,N−Dimethyloctanamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1118−92−9 : N,N−Dimethyloctanamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−90−0 : 2−(2−Ethoxyethoxy)ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−90−0 : 2−(2−Ethoxyethoxy)ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1119−40−0 : Dimethyl glutarate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1119−40−0 : Dimethyl glutarate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−96−6 : Bis(2−methoxyethyl) ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111−96−6 : Bis(2−methoxyethyl) ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111988−49−9 : Thiacloprid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111988−49−9 : Thiacloprid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111991−09−4 : Nicosulfuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 111991−09−4 : Nicosulfuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−01−0 : Sodium hexyldecyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−01−0 : Sodium hexyldecyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−04−3 : Octadecyl sulfate sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−04−3 : Octadecyl sulfate sodium salt

Agonist: 0.0045 Antagonist: 0.018

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−00−5 : Dodecyltrimethylammonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−00−5 : Dodecyltrimethylammonium chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−21−4 : Undecane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−21−4 : Undecane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−05−0 : Nonanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−05−0 : Nonanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−71−4 : 1,3−Propane sultone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1120−71−4 : 1,3−Propane sultone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−07−2 : 2−Butoxyethyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−07−2 : 2−Butoxyethyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−12−9 : 2−Undecanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−12−9 : 2−Undecanone

Agonist: 0.0019 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−14−1 : Octyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−14−1 : Octyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−18−5 : N,N−Dimethyldodecan−1−amine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−18−5 : N,N−Dimethyldodecan−1−amine

Agonist: 0 Antagonist: 2.2e−20

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112226−61−6 : Halofenozide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112226−61−6 : Halofenozide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−25−4 : 2−(Hexyloxy)ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−25−4 : 2−(Hexyloxy)ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−27−6 : Triethylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−27−6 : Triethylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112281−77−3 : Tetraconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112281−77−3 : Tetraconazole

Agonist: 0 Antagonist: 0.012

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−30−1 : 1−Decanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−30−1 : 1−Decanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−31−2 : Decanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−31−2 : Decanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−34−5 : 2−(2−Butoxyethoxy)ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−34−5 : 2−(2−Butoxyethoxy)ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−35−6 : 2−[2−(2−Methoxyethoxy)ethoxy]ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−35−6 : 2−[2−(2−Methoxyethoxy)ethoxy]ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−38−9 : 10−Undecenoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−38−9 : 10−Undecenoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112410−23−8 : Tebufenozide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112410−23−8 : Tebufenozide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−42−5 : 1−Undecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−42−5 : 1−Undecanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−49−2 : Triethylene glycol dimethyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−49−2 : Triethylene glycol dimethyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−50−5 : 2−[2−(2−Ethoxyethoxy)ethoxy]ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−50−5 : 2−[2−(2−Ethoxyethoxy)ethoxy]ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112529−15−4 : Pioglitazone hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112529−15−4 : Pioglitazone hydrochloride

Agonist: 0.0058 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−53−8 : 1−Dodecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−53−8 : 1−Dodecanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−55−0 : 1−Dodecanethiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−55−0 : 1−Dodecanethiol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−60−7 : Tetraethylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−60−7 : Tetraethylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−63−0 : Methyl linoleate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−63−0 : Methyl linoleate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−70−9 : 1−Tridecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−70−9 : 1−Tridecanol

Agonist: 0.004 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−72−1 : 1−Tetradecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−72−1 : 1−Tetradecanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112733−06−9 : Zenarestat

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112733−06−9 : Zenarestat

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−80−1 : Oleic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112−80−1 : Oleic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112809−51−5 : Letrozole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 112809−51−5 : Letrozole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 113136−77−9 : Cyclanilide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 113136−77−9 : Cyclanilide

Agonist: 0 Antagonist: 8.6e−05

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1134−23−2 : Cycloate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1134−23−2 : Cycloate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 113−48−4 : MGK−264

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 113−48−4 : MGK−264

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 113734−18−2 : CP−114271

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 113734−18−2 : CP−114271

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114−07−8 : Erythromycin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114−07−8 : Erythromycin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114−26−1 : Propoxur

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114−26−1 : Propoxur

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114311−32−9 : Imazamox

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114311−32−9 : Imazamox

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1143−38−0 : Anthralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1143−38−0 : Anthralin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114369−43−6 : Fenbuconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 114369−43−6 : Fenbuconazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−28−6 : Chlorendic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−28−6 : Chlorendic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−29−7 : Endosulfan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−29−7 : Endosulfan

Agonist: 0.034 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−32−2 : Dicofol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−32−2 : Dicofol

Agonist: 0 Antagonist: 0.039

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−39−9 : Bromophenol blue

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−39−9 : Bromophenol blue

Agonist: 0 Antagonist: 0.028

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1156−19−0 : Tolazamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1156−19−0 : Tolazamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−77−5 : Pentaerythritol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−77−5 : Pentaerythritol

Agonist: 0 Antagonist: 4e−05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−86−6 : Triphenyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−86−6 : Triphenyl phosphate

Agonist: 0.099 Antagonist: 0.061

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−95−7 : Linalyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−95−7 : Linalyl acetate

Agonist: 0 Antagonist: 8.8e−05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−96−8 : Tris(2−chloroethyl) phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 115−96−8 : Tris(2−chloroethyl) phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116−02−9 : 3,3,5−Trimethylcyclohexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116−02−9 : 3,3,5−Trimethylcyclohexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116−06−3 : Aldicarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116−06−3 : Aldicarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116255−48−2 : Bromuconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116255−48−2 : Bromuconazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116−25−6 : 1−(Hydroxymethyl)−5,5−dimethylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116−25−6 : 1−(Hydroxymethyl)−5,5−dimethylhydantoin

Agonist: 0.016 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1166−52−5 : Dodecyl gallate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1166−52−5 : Dodecyl gallate

Agonist: 0.004 Antagonist: 0.086

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116714−46−6 : Novaluron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 116714−46−6 : Novaluron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−08−8 : Tetrachlorophthalic anhydride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−08−8 : Tetrachlorophthalic anhydride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117337−19−6 : Fluthiacet−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117337−19−6 : Fluthiacet−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−39−5 : Quercetin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−39−5 : Quercetin

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117428−22−5 : Picoxystrobin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117428−22−5 : Picoxystrobin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117718−60−2 : Thiazopyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117718−60−2 : Thiazopyr

Agonist: 0.023 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−79−3 : 2−Aminoanthraquinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−79−3 : 2−Aminoanthraquinone

Agonist: 0.036 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−80−6 : Dichlone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−80−6 : Dichlone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−81−7 : Di(2−ethylhexyl) phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−81−7 : Di(2−ethylhexyl) phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−84−0 : Dioctyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−84−0 : Dioctyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−99−7 : 2−Hydroxybenzophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 117−99−7 : 2−Hydroxybenzophenone

Agonist: 0.029 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118134−30−8 : Spiroxamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118134−30−8 : Spiroxamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−47−8 : 1H−Pyrazole−3−carboxylic acid, 4,5−dihydro−5−oxo−1−(4−sulfophenyl)−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−47−8 : 1H−Pyrazole−3−carboxylic acid, 4,5−dihydro−5−oxo−1−(4−sulfophenyl)−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−52−5 : 1,3−Dichloro−5,5−dimethylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−52−5 : 1,3−Dichloro−5,5−dimethylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−55−8 : Phenyl salicylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−55−8 : Phenyl salicylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−56−9 : 3,3,5−Trimethylcyclohexyl salicylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−56−9 : 3,3,5−Trimethylcyclohexyl salicylate

Agonist: 0.041 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−58−1 : Benzyl salicylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−58−1 : Benzyl salicylate

Agonist: 0.019 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−71−8 : Maltol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−71−8 : Maltol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−79−6 : 2,4,6−Tribromophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−79−6 : 2,4,6−Tribromophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−82−1 : 4,4'−Methylenebis(2,6−di−t−butylphenol)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−82−1 : 4,4'−Methylenebis(2,6−di−t−butylphenol)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1189−08−8 : 1,3−Butyleneglycol dimethacrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1189−08−8 : 1,3−Butyleneglycol dimethacrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−93−4 : 2−Hydroxyacetophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 118−93−4 : 2−Hydroxyacetophenone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−07−3 : Octyl decyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−07−3 : Octyl decyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1191−50−0 : Sodium myristyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1191−50−0 : Sodium myristyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119168−77−3 : Tebufenpyrad

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119168−77−3 : Tebufenpyrad

Agonist: 0 Antagonist: 0.00015

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1192−52−5 : 4,5−Dichloro−3H−1,2−dithiol−3−one

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1192−52−5 : 4,5−Dichloro−3H−1,2−dithiol−3−one

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−36−8 : Methyl salicylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−36−8 : Methyl salicylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119446−68−3 : Difenoconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119446−68−3 : Difenoconazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1194−65−6 : Dichlobenil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1194−65−6 : Dichlobenil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−47−1 : 2,2'−Methylenebis(4−methyl−6−tert−butylphenol)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−47−1 : 2,2'−Methylenebis(4−methyl−6−tert−butylphenol)

Agonist: 0.001 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119515−38−7 : Icaridin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119515−38−7 : Icaridin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−53−9 : Benzoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−53−9 : Benzoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−61−9 : Benzophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−61−9 : Benzophenone

Agonist: 0.059 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−64−2 : Tetralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−64−2 : Tetralin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−90−4 : 3,3'−Dimethoxybenzidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−90−4 : 3,3'−Dimethoxybenzidine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−93−7 : 3,3'−Dimethylbenzidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 119−93−7 : 3,3'−Dimethylbenzidine

Agonist: 0.1 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120068−37−3 : Fipronil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120068−37−3 : Fipronil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120116−88−3 : Cyazofamid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120116−88−3 : Cyazofamid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−12−7 : Anthracene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−12−7 : Anthracene

Agonist: 0.008 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−14−9 : Veratraldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−14−9 : Veratraldehyde

Agonist: 0.035 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−18−3 : Naphthalene−2−sulfonic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−18−3 : Naphthalene−2−sulfonic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−32−1 : Clorophene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−32−1 : Clorophene

Agonist: 0.096 Antagonist: 0.043

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−36−5 : Dichlorprop

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−36−5 : Dichlorprop

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−46−7 : 1,3−Diphenyl−1,3−propanedione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−46−7 : 1,3−Diphenyl−1,3−propanedione

Agonist: 0.049 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−47−8 : Ethylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−47−8 : Ethylparaben

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120511−73−1 : Anastrozole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120511−73−1 : Anastrozole

Agonist: 0.018 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−51−4 : Benzyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−51−4 : Benzyl benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−55−8 : Diethylene glycol dibenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−55−8 : Diethylene glycol dibenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−56−9 : Triethylene glycol dibenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−56−9 : Triethylene glycol dibenzoate

Agonist: 0.03 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−61−6 : Dimethyl terephthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−61−6 : Dimethyl terephthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−65−0 : 2−((Dimethylamino)methyl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−65−0 : 2−((Dimethylamino)methyl)phenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−71−8 : 2−Methoxy−5−methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−71−8 : 2−Methoxy−5−methylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−72−9 : Indole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−72−9 : Indole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−80−9 : Catechol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−80−9 : Catechol

Agonist: 0.014 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−82−1 : 1,2,4−Trichlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−82−1 : 1,2,4−Trichlorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−83−2 : 2,4−Dichlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−83−2 : 2,4−Dichlorophenol

Agonist: 0.011 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−92−3 : Cyclopentanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−92−3 : Cyclopentanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−95−6 : 2,4−Bis(2−methylbutan−2−yl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 120−95−6 : 2,4−Bis(2−methylbutan−2−yl)phenol

Agonist: 0.0086 Antagonist: 0.005

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−00−6 : 2−tert−Butyl−4−methoxyphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−00−6 : 2−tert−Butyl−4−methoxyphenol

Agonist: 0.02 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 12108−13−3 : Manganese, tricarbonyl[(1,2,3,4,5−.eta.)−1−methyl−2,4−cyclopentadien−1−yl]−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 12108−13−3 : Manganese, tricarbonyl[(1,2,3,4,5−.eta.)−1−methyl−2,4−cyclopentadien−1−yl]−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−14−2 : 2,4−Dinitrotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−14−2 : 2,4−Dinitrotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−32−4 : 3−Ethoxy−4−hydroxybenzaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−32−4 : 3−Ethoxy−4−hydroxybenzaldehyde

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−33−5 : 4−Hydroxy−3−methoxybenzaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−33−5 : 4−Hydroxy−3−methoxybenzaldehyde

Agonist: 1.8e−05 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−39−1 : Ethyl 3−phenylglycidate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−39−1 : Ethyl 3−phenylglycidate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1214−39−7 : N−Benzyladenine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1214−39−7 : N−Benzyladenine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121552−61−2 : Cyprodinil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121552−61−2 : Cyprodinil

Agonist: 0.032 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−69−7 : N,N−Dimethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−69−7 : N,N−Dimethylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−75−5 : Malathion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−75−5 : Malathion

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−79−9 : Propyl gallate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−79−9 : Propyl gallate

Agonist: 0.097 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−91−5 : 1,3−Benzenedicarboxylic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 121−91−5 : 1,3−Benzenedicarboxylic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1219−38−1 : Octylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1219−38−1 : Octylparaben

Agonist: 0.38 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122008−85−9 : Cyhalofop−butyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122008−85−9 : Cyhalofop−butyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−14−5 : Fenitrothion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−14−5 : Fenitrothion

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−20−3 : Triisopropanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−20−3 : Triisopropanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−34−9 : Simazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−34−9 : Simazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−39−4 : Diphenylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−39−4 : Diphenylamine

Agonist: 0.02 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−40−7 : Pentylcinnamaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−40−7 : Pentylcinnamaldehyde

Agonist: 0.0064 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−42−9 : Propham

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−42−9 : Propham

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122453−73−0 : Chlorfenapyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122453−73−0 : Chlorfenapyr

Agonist: 0 Antagonist: 0.062

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−51−0 : Ethyl orthoformate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−51−0 : Ethyl orthoformate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−57−6 : Methyl styryl ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−57−6 : Methyl styryl ketone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−66−7 : 1,2−Diphenylhydrazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−66−7 : 1,2−Diphenylhydrazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−78−1 : Phenylacetaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−78−1 : Phenylacetaldehyde

Agonist: 0.0029 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122836−35−5 : Sulfentrazone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122836−35−5 : Sulfentrazone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−88−3 : 4−Chlorophenoxyacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−88−3 : 4−Chlorophenoxyacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−99−6 : 2−Phenoxyethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 122−99−6 : 2−Phenoxyethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−00−2 : 4−Morpholinepropanamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−00−2 : 4−Morpholinepropanamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−05−7 : 2−Ethylhexanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−05−7 : 2−Ethylhexanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−07−9 : 4−Ethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−07−9 : 4−Ethylphenol

Agonist: 0.0069 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−11−5 : 4−Methoxybenzaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−11−5 : 4−Methoxybenzaldehyde

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123122−55−4 : Candoxatril

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123122−55−4 : Candoxatril

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−17−1 : 2,6,8−Trimethyl−4−nonanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−17−1 : 2,6,8−Trimethyl−4−nonanol

Agonist: 0.0026 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−25−1 : Diethyl butanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−25−1 : Diethyl butanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123312−89−0 : Pymetrozine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123312−89−0 : Pymetrozine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−31−9 : Hydroquinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−31−9 : Hydroquinone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−33−1 : Maleic hydrazide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−33−1 : Maleic hydrazide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123343−16−8 : Pyrithiobac−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123343−16−8 : Pyrithiobac−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−35−3 : Myrcene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−35−3 : Myrcene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−42−2 : Diacetone alcohol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−42−2 : Diacetone alcohol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−66−0 : Ethyl hexanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−66−0 : Ethyl hexanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−77−3 : Azodicarbonamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−77−3 : Azodicarbonamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−92−2 : 3−Methylbutyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−92−2 : 3−Methylbutyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−96−6 : 2−Octanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−96−6 : 2−Octanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−99−9 : Nonanedioic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 123−99−9 : Nonanedioic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−04−9 : Hexanedioic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−04−9 : Hexanedioic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−07−2 : Octanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−07−2 : Octanoic acid

Agonist: 0.0059 Antagonist: 0.015

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−09−4 : 1,6−Hexanediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−09−4 : 1,6−Hexanediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−13−0 : Octanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−13−0 : Octanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−18−5 : Decane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−18−5 : Decane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1241−94−7 : 2−Ethylhexyl diphenyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1241−94−7 : 2−Ethylhexyl diphenyl phosphate

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−19−6 : Nonanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−19−6 : Nonanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−22−1 : 1−Dodecanamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−22−1 : 1−Dodecanamine

Agonist: 0.18 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 12427−38−2 : Maneb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 12427−38−2 : Maneb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124378−77−4 : Enadoline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124378−77−4 : Enadoline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−40−3 : Dimethylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−40−3 : Dimethylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124495−18−7 : Quinoxyfen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124495−18−7 : Quinoxyfen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−68−5 : 2−Amino−2−methylpropan−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−68−5 : 2−Amino−2−methylpropan−1−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−76−5 : Isoborneol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−76−5 : Isoborneol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−94−7 : Triamcinolone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 124−94−7 : Triamcinolone

Agonist: 0.057 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125116−23−6 : Metconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125116−23−6 : Metconazole

Agonist: 0.0076 Antagonist: 0.033

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125−12−2 : Isobornyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125−12−2 : Isobornyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125225−28−7 : Ipconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125225−28−7 : Ipconazole

Agonist: 0 Antagonist: 0.014

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125401−92−5 : Bispyribac−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125401−92−5 : Bispyribac−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125−84−8 : Aminoglutethimide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 125−84−8 : Aminoglutethimide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−00−1 : Diphenolic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−00−1 : Diphenolic acid

Agonist: 0.2 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1260−17−9 : Carminic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1260−17−9 : Carminic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−06−7 : 3−Bromo−1−chloro−5,5−dimethylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−06−7 : 3−Bromo−1−chloro−5,5−dimethylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−11−4 : 2−(Hydroxymethyl)−2−nitro−1,3−propanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−11−4 : 2−(Hydroxymethyl)−2−nitro−1,3−propanediol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−14−7 : Sucrose octaacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−14−7 : Sucrose octaacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−30−7 : 2,2−Dimethylpropane−1,3−diol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−30−7 : 2,2−Dimethylpropane−1,3−diol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−72−7 : Tris(2,3−dibromopropyl) phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−72−7 : Tris(2,3−dibromopropyl) phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−73−8 : Tributyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−73−8 : Tributyl phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126833−17−8 : Fenhexamid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126833−17−8 : Fenhexamid

Agonist: 0.21 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−86−3 : 2,4,7,9−Tetramethyl−5−decyne−4,7−diol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−86−3 : 2,4,7,9−Tetramethyl−5−decyne−4,7−diol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−92−1 : Sodium ethasulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−92−1 : Sodium ethasulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−98−7 : Methacrylonitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 126−98−7 : Methacrylonitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−07−1 : Hydroxyurea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−07−1 : Hydroxyurea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−19−5 : N,N−Dimethylacetamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−19−5 : N,N−Dimethylacetamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−25−3 : Methyl abietate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−25−3 : Methyl abietate

Agonist: 0.0093 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127308−82−1 : Zamifenacin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127308−82−1 : Zamifenacin

Agonist: 0.049 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−39−9 : Sodium 1,4−diisobutyl sulfosuccinate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−39−9 : Sodium 1,4−diisobutyl sulfosuccinate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−41−3 : alpha−Ionone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−41−3 : alpha−Ionone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−47−9 : Retinol acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−47−9 : Retinol acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−51−5 : alpha−Isomethylionone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 127−51−5 : alpha−Isomethylionone

Agonist: 0.016 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−04−1 : Sodium dimethyldithiocarbamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−04−1 : Sodium dimethyldithiocarbamate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−37−0 : Butylated hydroxytoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−37−0 : Butylated hydroxytoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−39−2 : 2,6−Di−tert−butylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−39−2 : 2,6−Di−tert−butylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128639−02−1 : Carfentrazone−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128639−02−1 : Carfentrazone−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−95−0 : 1,4−Diaminoanthraquinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 128−95−0 : 1,4−Diaminoanthraquinone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129−00−0 : Pyrene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129−00−0 : Pyrene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129−06−6 : Sodium warfarin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129−06−6 : Sodium warfarin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129−17−9 : Sulfan blue

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129−17−9 : Sulfan blue

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129453−61−8 : Fulvestrant

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129453−61−8 : Fulvestrant

Agonist: 0 Antagonist: 0.91

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129630−19−9 : Pyraflufen−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 129630−19−9 : Pyraflufen−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1300−72−7 : Sodium xylenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1300−72−7 : Sodium xylenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1300−73−8 : Dimethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1300−73−8 : Dimethylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 130−14−3 : Sodium 1−naphthalenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 130−14−3 : Sodium 1−naphthalenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1303−11−3 : Indium arsenide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1303−11−3 : Indium arsenide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13071−79−9 : Terbufos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13071−79−9 : Terbufos

Agonist: 0.063 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−11−3 : Dimethyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−11−3 : Dimethyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−17−9 : Diallyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−17−9 : Diallyl phthalate

Agonist: 0.021 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−18−0 : Dipentyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−18−0 : Dipentyl phthalate

Agonist: 0.024 Antagonist: 0.06

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131341−86−1 : Fludioxonil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131341−86−1 : Fludioxonil

Agonist: 0.056 Antagonist: 0.0066

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−55−5 : 2,2',4,4'−Tetrahydroxybenzophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−55−5 : 2,2',4,4'−Tetrahydroxybenzophenone

Agonist: 0.56 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−56−6 : 2,4−Dihydroxybenzophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−56−6 : 2,4−Dihydroxybenzophenone

Agonist: 0.4 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−57−7 : 2−Hydroxy−4−methoxybenzophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−57−7 : 2−Hydroxy−4−methoxybenzophenone

Agonist: 0.092 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−70−4 : Monobutyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131−70−4 : Monobutyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13171−00−1 : 1−(6−tert−Butyl−1,1−dimethyl−2,3−dihydro−1H−inden−4−yl)ethanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13171−00−1 : 1−(6−tert−Butyl−1,1−dimethyl−2,3−dihydro−1H−inden−4−yl)ethanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131807−57−3 : Famoxadone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131807−57−3 : Famoxadone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131860−33−8 : Azoxystrobin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131860−33−8 : Azoxystrobin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13194−48−4 : Ethoprop

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13194−48−4 : Ethoprop

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131983−72−7 : Triticonazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 131983−72−7 : Triticonazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1320−07−6 : C.I. Acid Orange 24, monosodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1320−07−6 : C.I. Acid Orange 24, monosodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1321−74−0 : Divinylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1321−74−0 : Divinylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1323−19−9 : Sodium 2,4,7−tri(propan−2−yl)naphthalene−1−sulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1323−19−9 : Sodium 2,4,7−tri(propan−2−yl)naphthalene−1−sulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1323−38−2 : Glyceryl monoricinoleate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1323−38−2 : Glyceryl monoricinoleate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13254−34−7 : 2,6−Dimethyl−2−heptanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13254−34−7 : 2,6−Dimethyl−2−heptanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 132−64−9 : Dibenzofuran

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 132−64−9 : Dibenzofuran

Agonist: 0.0044 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 132−65−0 : Dibenzothiophene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 132−65−0 : Dibenzothiophene

Agonist: 0.0063 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13292−46−1 : Rifampicin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13292−46−1 : Rifampicin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13301−61−6 : C.I. Disperse Orange 37

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13301−61−6 : C.I. Disperse Orange 37

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133−06−2 : Captan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133−06−2 : Captan

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133−07−3 : Folpet

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133−07−3 : Folpet

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1330−78−5 : Tricresyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1330−78−5 : Tricresyl phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1330−86−5 : Diisooctyl adipate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1330−86−5 : Diisooctyl adipate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13311−84−7 : Flutamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13311−84−7 : Flutamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1333−39−7 : Phenolsulfonic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1333−39−7 : Phenolsulfonic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1335−46−2 : Ionone, methyl−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1335−46−2 : Ionone, methyl−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1338−43−8 : Sorbitan, mono−(9Z)−9−octadecenoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1338−43−8 : Sorbitan, mono−(9Z)−9−octadecenoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133855−98−8 : Epoxiconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133855−98−8 : Epoxiconazole

Agonist: 0 Antagonist: 0.04

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133−90−4 : Chloramben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 133−90−4 : Chloramben

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134002−60−1 : CP−085958

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134002−60−1 : CP−085958

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−03−2 : Sodium L−ascorbate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−03−2 : Sodium L−ascorbate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−20−3 : Methyl 2−aminobenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−20−3 : Methyl 2−aminobenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−31−6 : 8−Hydroxyquinoline sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−31−6 : 8−Hydroxyquinoline sulfate

Agonist: 0.014 Antagonist: 0.0012

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134523−03−8 : Atorvastatin calcium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134523−03−8 : Atorvastatin calcium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134605−64−4 : Butafenacil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134605−64−4 : Butafenacil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−62−3 : DEET

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 134−62−3 : DEET

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13463−41−7 : Zinc pyrithione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13463−41−7 : Zinc pyrithione

Agonist: 0 Antagonist: 0.33

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135080−03−4 : CP−100829

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135080−03−4 : CP−100829

Agonist: 0 Antagonist: 0.02

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135158−54−2 : Acibenzolar−S−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135158−54−2 : Acibenzolar−S−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135−19−3 : 2−Naphthalenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135−19−3 : 2−Naphthalenol

Agonist: 0.15 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135−20−6 : Cupferron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135−20−6 : Cupferron

Agonist: 0.018 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135410−20−7 : Acetamiprid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 135410−20−7 : Acetamiprid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 136−45−8 : Dipropyl pyridine−2,5−dicarboxylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 136−45−8 : Dipropyl pyridine−2,5−dicarboxylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 136−60−7 : Butyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 136−60−7 : Butyl benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13674−84−5 : Tris(2−chloroisopropyl)phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13674−84−5 : Tris(2−chloroisopropyl)phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13674−87−8 : Tris(1,3−dichloro−2−propyl)phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13674−87−8 : Tris(1,3−dichloro−2−propyl)phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 136−77−6 : 4−Hexylresorcinol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 136−77−6 : 4−Hexylresorcinol

Agonist: 0.063 Antagonist: 0.011

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13680−35−8 : 4,4'−Methylenebis(2,6−diethylaniline)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13680−35−8 : 4,4'−Methylenebis(2,6−diethylaniline)

Agonist: 0 Antagonist: 0.063

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13684−56−5 : Desmedipham

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13684−56−5 : Desmedipham

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13684−63−4 : Phenmedipham

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13684−63−4 : Phenmedipham

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−26−8 : Thiram

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−26−8 : Thiram

Agonist: 0.0052 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−30−4 : Ziram

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−30−4 : Ziram

Agonist: 0 Antagonist: 0.043

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−42−8 : Metam−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−42−8 : Metam−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13755−29−8 : Sodium tetrafluoroborate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13755−29−8 : Sodium tetrafluoroborate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−66−6 : Ascorbyl palmitate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 137−66−6 : Ascorbyl palmitate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 138−22−7 : Butyl lactate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 138−22−7 : Butyl lactate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 138261−41−3 : Imidacloprid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 138261−41−3 : Imidacloprid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13826−35−2 : 3−Phenoxybenzenemethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 13826−35−2 : 3−Phenoxybenzenemethanol

Agonist: 0.093 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 138−86−3 : Limonene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 138−86−3 : Limonene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−02−6 : Sodium phenolate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−02−6 : Sodium phenolate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−13−9 : Nitrilotriacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−13−9 : Nitrilotriacetic acid

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139149−55−6 : SB202235

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139149−55−6 : SB202235

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139290−65−6 : Volinanserin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139290−65−6 : Volinanserin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139340−56−0 : Darbufelone mesylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139340−56−0 : Darbufelone mesylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−40−2 : Propazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−40−2 : Propazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−87−7 : Ethyl diethanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−87−7 : Ethyl diethanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−88−8 : 7−Ethyl−2−methyl−4−undecanolsulfate, sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−88−8 : 7−Ethyl−2−methyl−4−undecanolsulfate, sodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−96−8 : Dodecyl sulfate triethanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 139−96−8 : Dodecyl sulfate triethanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−08−9 : Tris(2−chloroethyl) phosphite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−08−9 : Tris(2−chloroethyl) phosphite

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−10−3 : Cinnamic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−10−3 : Cinnamic acid

Agonist: 0.11 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−11−4 : Benzyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−11−4 : Benzyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1401−55−4 : Tannic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1401−55−4 : Tannic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−31−8 : 1−(2−Aminoethyl)piperazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−31−8 : 1−(2−Aminoethyl)piperazine

Agonist: 0.0065 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−38−5 : 4−Chlorophenylurea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−38−5 : 4−Chlorophenylurea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−56−7 : Fenaminosulf

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−56−7 : Fenaminosulf

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−64−7 : Pentamidine isethionate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−64−7 : Pentamidine isethionate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−66−9 : 4−(1,1,3,3−Tetramethylbutyl)phenol

Agonist: 0.56 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−67−0 : Estragole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−67−0 : Estragole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−95−4 : Dimethylolurea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 140−95−4 : Dimethylolurea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−04−8 : Diisobutyl adipate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−04−8 : Diisobutyl adipate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141112−29−0 : Isoxaflutole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141112−29−0 : Isoxaflutole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−22−0 : 9−Octadecenoic acid, 12−hydroxy−, (9Z,12R)−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−22−0 : 9−Octadecenoic acid, 12−hydroxy−, (9Z,12R)−

Agonist: 0 Antagonist: 0.028

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−32−2 : Butyl acrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−32−2 : Butyl acrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−43−5 : Ethanolamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−43−5 : Ethanolamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141517−21−7 : Trifloxystrobin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141517−21−7 : Trifloxystrobin

Agonist: 0 Antagonist: 0.00013

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−66−2 : Dicrotophos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−66−2 : Dicrotophos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−79−7 : 4−Methylpent−3−en−2−one

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 141−79−7 : 4−Methylpent−3−en−2−one

Agonist: 0.14 Antagonist: 0.051

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−04−1 : Aniline hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−04−1 : Aniline hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−16−5 : Bis(2−ethylhexyl) maleate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−16−5 : Bis(2−ethylhexyl) maleate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−18−7 : 1−Monolaurin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−18−7 : 1−Monolaurin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−31−4 : Sodium octyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−31−4 : Sodium octyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14233−37−5 : 1,4−Bis(N−isopropylamino)anthraquinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14233−37−5 : 1,4−Bis(N−isopropylamino)anthraquinone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142459−58−3 : Flufenacet

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142459−58−3 : Flufenacet

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−62−1 : Hexanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−62−1 : Hexanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−87−0 : Sodium decyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 142−87−0 : Sodium decyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−07−7 : Dodecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−07−7 : Dodecanoic acid

Agonist: 0 Antagonist: 0.013

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−08−8 : 1−Nonanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−08−8 : 1−Nonanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−22−6 : 2−[2−(2−Butoxyethoxy)ethoxy]ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−22−6 : 2−[2−(2−Butoxyethoxy)ethoxy]ethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143390−89−0 : Kresoxim−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143390−89−0 : Kresoxim−methyl

Agonist: 0.01 Antagonist: 0.075

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1434−54−4 : Pregnenolone carbonitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1434−54−4 : Pregnenolone carbonitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−50−0 : Kepone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−50−0 : Kepone

Agonist: 0.23 Antagonist: 0.029

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14351−66−7 : Sodium abietate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14351−66−7 : Sodium abietate

Agonist: 0.0022 Antagonist: 0.017

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14371−10−9 : (2E)−3−Phenylprop−2−enal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14371−10−9 : (2E)−3−Phenylprop−2−enal

Agonist: 0.013 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−74−8 : Phenol red

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 143−74−8 : Phenol red

Agonist: 0.04 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 144−49−0 : Fluoroacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 144−49−0 : Fluoroacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 144550−36−7 : Iodosulfuron−methyl−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 144550−36−7 : Iodosulfuron−methyl−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1445−75−6 : Diisopropyl methylphosphonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1445−75−6 : Diisopropyl methylphosphonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 144−62−7 : Oxalic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 144−62−7 : Oxalic acid

Agonist: 0.017 Antagonist: 0.044

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 145701−21−9 : Diclosulam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 145701−21−9 : Diclosulam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 145−73−3 : Endothal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 145−73−3 : Endothal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 145742−28−5 : CP−122721

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 145742−28−5 : CP−122721

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1459−93−4 : Dimethyl isophthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1459−93−4 : Dimethyl isophthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1461−22−9 : Tributyltin chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1461−22−9 : Tributyltin chloride

Agonist: 0 Antagonist: 0.072

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1461−25−2 : Tetrabutyltin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1461−25−2 : Tetrabutyltin

Agonist: 0 Antagonist: 0.007

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 147−24−0 : Diphenhydramine hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 147−24−0 : Diphenhydramine hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14765−30−1 : 2−sec−Butylcyclohexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14765−30−1 : 2−sec−Butylcyclohexanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1477−55−0 : 1,3−Benzenedimethanamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1477−55−0 : 1,3−Benzenedimethanamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 147−81−9 : Arabinose

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 147−81−9 : Arabinose

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1478−61−1 : Bisphenol AF

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1478−61−1 : Bisphenol AF

Agonist: 0.82 Antagonist: 0.0038

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14816−18−3 : Phoxim

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14816−18−3 : Phoxim

Agonist: 0.19 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 148−24−3 : 8−Hydroxyquinoline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 148−24−3 : 8−Hydroxyquinoline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 148477−71−8 : Spirodiclofen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 148477−71−8 : Spirodiclofen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 148−79−8 : Thiabendazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 148−79−8 : Thiabendazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1490−04−6 : Menthol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1490−04−6 : Menthol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14901−07−6 : 4−(2,6,6−Trimethyl−cyclohex−1−enyl)−but−3−en−2−one

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 14901−07−6 : 4−(2,6,6−Trimethyl−cyclohex−1−enyl)−but−3−en−2−one

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149062−75−9 : PharmaGSID_47259

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149062−75−9 : PharmaGSID_47259

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149−30−4 : 2−Mercaptobenzothiazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149−30−4 : 2−Mercaptobenzothiazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149−57−5 : 2−Ethylhexanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149−57−5 : 2−Ethylhexanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149877−41−8 : Bifenazate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149877−41−8 : Bifenazate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149979−41−9 : Tepraloxydim

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 149979−41−9 : Tepraloxydim

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−13−0 : 4−Aminobenzoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−13−0 : 4−Aminobenzoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15046−75−0 : Sodium 2−methylbenzenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15046−75−0 : Sodium 2−methylbenzenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−68−5 : Monuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−68−5 : Monuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−76−5 : 4−Methoxyphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−76−5 : 4−Methoxyphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−78−7 : Hydroquinone dimethyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 150−78−7 : Hydroquinone dimethyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 151−05−3 : Dimethylbenzylcarbinyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 151−05−3 : Dimethylbenzylcarbinyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 151−21−3 : Sodium dodecyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 151−21−3 : Sodium dodecyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15214−89−8 : 2−Acrylamido−2−methyl−1−propanesulfonic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15214−89−8 : 2−Acrylamido−2−methyl−1−propanesulfonic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15299−99−7 : Napropamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15299−99−7 : Napropamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15307−79−6 : Diclofenac sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15307−79−6 : Diclofenac sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15310−01−7 : Benodanil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15310−01−7 : Benodanil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 153233−91−1 : Etoxazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 153233−91−1 : Etoxazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 153719−23−4 : Thiamethoxam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 153719−23−4 : Thiamethoxam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1541−81−7 : 4−Dodecylmorpholine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1541−81−7 : 4−Dodecylmorpholine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 154−42−7 : 6−Thioguanine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 154−42−7 : 6−Thioguanine

Agonist: 0 Antagonist: 0.00013

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15499−27−1 : 4−Butylchlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15499−27−1 : 4−Butylchlorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 155569−91−8 : Emamectin benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 155569−91−8 : Emamectin benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1559−34−8 : 3,6,9,12−Tetraoxahexadecan−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1559−34−8 : 3,6,9,12−Tetraoxahexadecan−1−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1559−35−9 : 2−(2−Ethylhexyloxy)ethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1559−35−9 : 2−(2−Ethylhexyloxy)ethanol

Agonist: 6e−07 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 155990−20−8 : SR271425

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 155990−20−8 : SR271425

Agonist: 0.044 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156052−68−5 : Zoxamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156052−68−5 : Zoxamide

Agonist: 0 Antagonist: 0.025

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156−10−5 : 4−Nitrosodiphenylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156−10−5 : 4−Nitrosodiphenylamine

Agonist: 0.035 Antagonist: 8e−04

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1563−38−8 : 2,3−Dihydro−2,2−dimethyl−7−benzofuranol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1563−38−8 : 2,3−Dihydro−2,2−dimethyl−7−benzofuranol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1563−66−2 : Carbofuran

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1563−66−2 : Carbofuran

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156−43−4 : 4−Ethoxyaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156−43−4 : 4−Ethoxyaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156−60−5 : (E)−1,2−Dichloroethylene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 156−60−5 : (E)−1,2−Dichloroethylene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1569−01−3 : 1−Propoxy−2−propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1569−01−3 : 1−Propoxy−2−propanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1569−02−4 : 1−Ethoxy−2−propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1569−02−4 : 1−Ethoxy−2−propanol

Agonist: 0.00084 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1570−64−5 : 4−Chloro−2−methylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1570−64−5 : 4−Chloro−2−methylphenol

Agonist: 0.019 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15708−41−5 : Ethylenediaminetetraacetic acid ferric sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15708−41−5 : Ethylenediaminetetraacetic acid ferric sodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 158081−99−3 : CP−105696

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 158081−99−3 : CP−105696

Agonist: 0 Antagonist: 0.025

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1582−09−8 : Trifluralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1582−09−8 : Trifluralin

Agonist: 0.027 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 159138−81−5 : Cariporide mesylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 159138−81−5 : Cariporide mesylate

Agonist: 0.014 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1596−84−5 : Daminozide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1596−84−5 : Daminozide

Agonist: 0.049 Antagonist: 0.00084

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15972−60−8 : Alachlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 15972−60−8 : Alachlor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16079−88−2 : Bromo−3−chloro−5,5−dimethylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16079−88−2 : Bromo−3−chloro−5,5−dimethylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1610−18−0 : Prometon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1610−18−0 : Prometon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 161050−58−4 : Methoxyfenozide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 161050−58−4 : Methoxyfenozide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 161326−34−7 : Fenamidone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 161326−34−7 : Fenamidone

Agonist: 0.017 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16219−75−3 : 5−Ethylidene−2−norbornene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16219−75−3 : 5−Ethylidene−2−norbornene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1625−91−8 : 4,4'−Di−tert−butylbiphenyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1625−91−8 : 4,4'−Di−tert−butylbiphenyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 162706−14−1 : UK−156819

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 162706−14−1 : UK−156819

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1632−73−1 : Fenchol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1632−73−1 : Fenchol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1634−78−2 : Malaoxon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1634−78−2 : Malaoxon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 163520−33−0 : Isoxadifen−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 163520−33−0 : Isoxadifen−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1638−22−8 : 4−Butylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1638−22−8 : 4−Butylphenol

Agonist: 0.14 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16423−68−0 : FD&C Red 3

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16423−68−0 : FD&C Red 3

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1646−75−9 : Aldicarb oxime

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1646−75−9 : Aldicarb oxime

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1646−87−3 : Aldicarb sulfoxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1646−87−3 : Aldicarb sulfoxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1646−88−4 : Aldoxycarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1646−88−4 : Aldoxycarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 165252−70−0 : Dinotefuran

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 165252−70−0 : Dinotefuran

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16587−71−6 : 4−(tert−Pentyl)−cyclohexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16587−71−6 : 4−(tert−Pentyl)−cyclohexanone

Agonist: 0.04 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 166412−78−8 : Diisononyl cyclohexane−1,2−dicarboxylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 166412−78−8 : Diisononyl cyclohexane−1,2−dicarboxylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16672−87−0 : Ethephon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16672−87−0 : Ethephon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1671−75−6 : Heptanophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1671−75−6 : Heptanophenone

Agonist: 0.0051 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16752−77−5 : Methomyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16752−77−5 : Methomyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1675−54−3 : Bisphenol A diglycidyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1675−54−3 : Bisphenol A diglycidyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16893−85−9 : Sodium hexafluorosilicate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 16893−85−9 : Sodium hexafluorosilicate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1689−84−5 : Bromoxynil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1689−84−5 : Bromoxynil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 169590−42−5 : Celecoxib

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 169590−42−5 : Celecoxib

Agonist: 0 Antagonist: 0.023

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1698−60−8 : Chloridazon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1698−60−8 : Chloridazon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1702−17−6 : Clopyralid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1702−17−6 : Clopyralid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 171866−31−2 : CP−283097

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 171866−31−2 : CP−283097

Agonist: 0.017 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1724−39−6 : Cyclododecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1724−39−6 : Cyclododecanol

Agonist: 0.04 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 173584−44−6 : Indoxacarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 173584−44−6 : Indoxacarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17372−87−1 : Eosin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17372−87−1 : Eosin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1742−14−9 : 1,1−Bis(3,4−dimethylphenyl)ethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1742−14−9 : 1,1−Bis(3,4−dimethylphenyl)ethane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17465−86−0 : gamma−Cyclodextrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17465−86−0 : gamma−Cyclodextrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 175013−18−0 : Pyraclostrobin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 175013−18−0 : Pyraclostrobin

Agonist: 0 Antagonist: 0.00067

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1760−24−3 : N−[3−(Trimethoxysilyl)propyl]ethane−1,2−diamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1760−24−3 : N−[3−(Trimethoxysilyl)propyl]ethane−1,2−diamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1762−95−4 : Thiocyanic acid, ammonium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1762−95−4 : Thiocyanic acid, ammonium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1763−23−1 : PFOS

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1763−23−1 : PFOS

Agonist: 0.0012 Antagonist: 0.0034

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17696−62−7 : Phenylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17696−62−7 : Phenylparaben

Agonist: 0.37 Antagonist: 0.017

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 177785−47−6 : PharmaGSID_47261

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 177785−47−6 : PharmaGSID_47261

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17796−82−6 : N−(Cyclohexylthio)phthalimide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17796−82−6 : N−(Cyclohexylthio)phthalimide

Agonist: 0.00084 Antagonist: 0.0033

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17804−35−2 : Benomyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17804−35−2 : Benomyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17924−92−4 : Zearalenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 17924−92−4 : Zearalenone

Agonist: 0.89 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 179465−71−5 : CJ−013790

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 179465−71−5 : CJ−013790

Agonist: 0.02 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 180084−01−9 : SB236057A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 180084−01−9 : SB236057A

Agonist: 0 Antagonist: 0.038

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1806−26−4 : 4−Octylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1806−26−4 : 4−Octylphenol

Agonist: 0.15 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 181274−15−7 : Propoxycarbazone−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 181274−15−7 : Propoxycarbazone−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 181274−17−9 : Flucarbazone−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 181274−17−9 : Flucarbazone−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 181640−09−5 : SR144190

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 181640−09−5 : SR144190

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 18172−67−3 : (−)−beta−Pinene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 18172−67−3 : (−)−beta−Pinene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1825−21−4 : Pentachloroanisole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1825−21−4 : Pentachloroanisole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1836−75−5 : Nitrofen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1836−75−5 : Nitrofen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1843−05−6 : Octabenzone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1843−05−6 : Octabenzone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 184653−84−7 : Carabersat

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 184653−84−7 : Carabersat

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1861−32−1 : Chlorthal−dimethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1861−32−1 : Chlorthal−dimethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1861−40−1 : Benfluralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1861−40−1 : Benfluralin

Agonist: 0.041 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 186392−65−4 : Ingliforib

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 186392−65−4 : Ingliforib

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1873−88−7 : 1,1,1,3,5,5,5−Heptamethyltrisiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1873−88−7 : 1,1,1,3,5,5,5−Heptamethyltrisiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 188425−85−6 : Boscalid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 188425−85−6 : Boscalid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 188489−07−8 : Flufenpyr−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 188489−07−8 : Flufenpyr−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 189003−92−7 : Trelanserin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 189003−92−7 : Trelanserin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 18924−66−8 : 2,2'−(Tetradecylimino)diethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 18924−66−8 : 2,2'−(Tetradecylimino)diethanol

Agonist: 4e−05 Antagonist: 0.086

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1897−45−6 : Chlorothalonil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1897−45−6 : Chlorothalonil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 18979−55−0 : 4−(Hexyloxy)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 18979−55−0 : 4−(Hexyloxy)phenol

Agonist: 0.23 Antagonist: 0.0038

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19044−88−3 : Oryzalin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19044−88−3 : Oryzalin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1907−65−9 : N−Butyl−p−toluenesulfonamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1907−65−9 : N−Butyl−p−toluenesulfonamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1912−24−9 : Atrazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1912−24−9 : Atrazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1918−00−9 : Dicamba

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1918−00−9 : Dicamba

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1918−02−1 : Picloram

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1918−02−1 : Picloram

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1918−16−7 : Propachlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1918−16−7 : Propachlor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1929−73−3 : 2,4−D−Butotyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1929−73−3 : 2,4−D−Butotyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1929−77−7 : Vernolate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1929−77−7 : Vernolate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1929−82−4 : Nitrapyrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1929−82−4 : Nitrapyrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1934−21−0 : FD&C Yellow 5

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1934−21−0 : FD&C Yellow 5

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1936−15−8 : C.I. Acid Orange 10

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1936−15−8 : C.I. Acid Orange 10

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 194098−25−4 : CP−409092

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 194098−25−4 : CP−409092

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1948−33−0 : tert−Butylhydroquinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1948−33−0 : tert−Butylhydroquinone

Agonist: 0.0053 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19666−30−9 : Oxadiazon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19666−30−9 : Oxadiazon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 196808−45−4 : Farglitazar

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 196808−45−4 : Farglitazar

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 197077−55−7 : UK−333747

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 197077−55−7 : UK−333747

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19774−82−4 : Amiodarone hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19774−82−4 : Amiodarone hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19780−11−1 : (2−Dodecenyl)succinic anhydride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 19780−11−1 : (2−Dodecenyl)succinic anhydride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1987−50−4 : 4−Heptylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 1987−50−4 : 4−Heptylphenol

Agonist: 0.15 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 199119−58−9 : Trifloxysulfuron−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 199119−58−9 : Trifloxysulfuron−sodium

Agonist: 0.003 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 199171−88−5 : CP−401387

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 199171−88−5 : CP−401387

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 199584−38−8 : 1−Methoxy−4−tert−pentylcyclohexane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 199584−38−8 : 1−Methoxy−4−tert−pentylcyclohexane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2008−41−5 : Butylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2008−41−5 : Butylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 200940−23−4 : SB243213A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 200940−23−4 : SB243213A

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2016−57−1 : 1−Decanamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2016−57−1 : 1−Decanamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20265−97−8 : 4−Methoxyaniline hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20265−97−8 : 4−Methoxyaniline hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2031−67−6 : Triethoxymethylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2031−67−6 : Triethoxymethylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20325−40−0 : 3,3'−Dimethoxybenzidine dihydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20325−40−0 : 3,3'−Dimethoxybenzidine dihydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 203942−49−8 : UK−337312

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 203942−49−8 : UK−337312

Agonist: 0.0024 Antagonist: 0.011

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2043−57−4 : 1H,1H,2H,2H−Perfluorooctyl iodide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2043−57−4 : 1H,1H,2H,2H−Perfluorooctyl iodide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2044−64−6 : N,N−Dimethylacetoacetamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2044−64−6 : N,N−Dimethylacetoacetamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2058−46−0 : Oxytetracycline hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2058−46−0 : Oxytetracycline hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2058−94−8 : Perfluoroundecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2058−94−8 : Perfluoroundecanoic acid

Agonist: 0.0038 Antagonist: 0.013

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 205−99−2 : Benzo(b)fluoranthene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 205−99−2 : Benzo(b)fluoranthene

Agonist: 0.01 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 206−44−0 : Fluoranthene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 206−44−0 : Fluoranthene

Agonist: 0.01 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 207736−05−8 : CI−1029

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 207736−05−8 : CI−1029

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20780−48−7 : 3,7−Dimethyloctan−3−yl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20780−48−7 : 3,7−Dimethyloctan−3−yl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2078−54−8 : Propofol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2078−54−8 : Propofol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20830−75−5 : Digoxin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 20830−75−5 : Digoxin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 208−96−8 : Acenaphthylene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 208−96−8 : Acenaphthylene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2104−64−5 : EPN

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2104−64−5 : EPN

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 210631−68−8 : Topramezone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 210631−68−8 : Topramezone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 210826−40−7 : CP−456773

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 210826−40−7 : CP−456773

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21087−64−9 : Metribuzin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21087−64−9 : Metribuzin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 210880−92−5 : Clothianidin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 210880−92−5 : Clothianidin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2110−18−1 : 2−(3−Phenylpropyl)pyridine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2110−18−1 : 2−(3−Phenylpropyl)pyridine

Agonist: 0.017 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21145−77−7 : 6−Acetyl−1,1,2,4,4,7−hexamethyltetralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21145−77−7 : 6−Acetyl−1,1,2,4,4,7−hexamethyltetralin

Agonist: 0.054 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2122−70−5 : Ethyl 1−naphthaleneacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2122−70−5 : Ethyl 1−naphthaleneacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21245−02−3 : 2−Ethylhexyl 4−(dimethylamino)benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21245−02−3 : 2−Ethylhexyl 4−(dimethylamino)benzoate

Agonist: 0.0098 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2144−53−8 : Tridecafluorohexylethyl methacrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2144−53−8 : Tridecafluorohexylethyl methacrylate

Agonist: 0.01 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 214535−77−0 : CP−457677

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 214535−77−0 : CP−457677

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 215297−27−1 : UK−343664

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 215297−27−1 : UK−343664

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2155−70−6 : Tributyltin methacrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2155−70−6 : Tributyltin methacrylate

Agonist: 0 Antagonist: 0.083

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21564−17−0 : 2−(Thiocyanomethylthio)benzothiazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21564−17−0 : 2−(Thiocyanomethylthio)benzothiazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2164−17−2 : Fluometuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2164−17−2 : Fluometuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21662−09−9 : (4Z)−4−Decenal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21662−09−9 : (4Z)−4−Decenal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21725−46−2 : Cyanazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 21725−46−2 : Cyanazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2176−62−7 : Pentachloropyridine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2176−62−7 : Pentachloropyridine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 219714−96−2 : Penoxsulam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 219714−96−2 : Penoxsulam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 219790−72−4 : SB281832

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 219790−72−4 : SB281832

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22047−49−0 : 2−Ethylhexyl octadecanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22047−49−0 : 2−Ethylhexyl octadecanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 220860−50−4 : CP−457920

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 220860−50−4 : CP−457920

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 221246−12−4 : Fandosentan potassium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 221246−12−4 : Fandosentan potassium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2212−67−1 : Molinate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2212−67−1 : Molinate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 221671−62−1 : SR146131

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 221671−62−1 : SR146131

Agonist: 0 Antagonist: 0.007

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22224−92−6 : Fenamiphos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22224−92−6 : Fenamiphos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22248−79−9 : Z−Tetrachlorvinphos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22248−79−9 : Z−Tetrachlorvinphos

Agonist: 0 Antagonist: 7.7e−05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22260−51−1 : Bromocriptine mesylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22260−51−1 : Bromocriptine mesylate

Agonist: 0 Antagonist: 0.034

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2231−57−4 : Thiocarbazide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2231−57−4 : Thiocarbazide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2243−62−1 : 1,5−Naphthalenediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2243−62−1 : 1,5−Naphthalenediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2244−21−5 : Potassium dichloroisocyanurate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2244−21−5 : Potassium dichloroisocyanurate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22781−23−3 : Bendiocarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22781−23−3 : Bendiocarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22839−47−0 : Aspartame

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22839−47−0 : Aspartame

Agonist: 0.0044 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22915−73−7 : Hexane−1,6−diyl dibenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 22915−73−7 : Hexane−1,6−diyl dibenzoate

Agonist: 0.0058 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23031−36−9 : Prallethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23031−36−9 : Prallethrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2303−17−5 : Tri−allate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2303−17−5 : Tri−allate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23089−26−1 : Levomenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23089−26−1 : Levomenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 230954−09−3 : CP−544439

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 230954−09−3 : CP−544439

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2310−17−0 : Phosalone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2310−17−0 : Phosalone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23103−98−2 : Pirimicarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23103−98−2 : Pirimicarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2312−35−8 : Propargite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2312−35−8 : Propargite

Agonist: 0 Antagonist: 0.00013

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23135−22−0 : Oxamyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23135−22−0 : Oxamyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23184−66−9 : Butachlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23184−66−9 : Butachlor

Agonist: 0 Antagonist: 0.0073

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2321−07−5 : Fluorescein

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2321−07−5 : Fluorescein

Agonist: 8e−04 Antagonist: 0.026

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23386−52−9 : Dicyclohexyl sodium sulfosuccinate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23386−52−9 : Dicyclohexyl sodium sulfosuccinate

Agonist: 0.00016 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23422−53−9 : Formetanate hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23422−53−9 : Formetanate hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2353−45−9 : FD&C Green No. 3

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2353−45−9 : FD&C Green No. 3

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23564−05−8 : Thiophanate−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23564−05−8 : Thiophanate−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23564−06−9 : Thiophanate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23564−06−9 : Thiophanate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23593−75−1 : Clotrimazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23593−75−1 : Clotrimazole

Agonist: 0 Antagonist: 0.0065

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23779−32−0 : 1−[3−(Triethoxysilyl)propyl]urea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23779−32−0 : 1−[3−(Triethoxysilyl)propyl]urea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2385−85−5 : Mirex

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2385−85−5 : Mirex

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2386−87−0 : UT−632

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2386−87−0 : UT−632

Agonist: 0.0052 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2390−60−5 : Basic Blue 7

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2390−60−5 : Basic Blue 7

Agonist: 0 Antagonist: 0.065

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2392−39−4 : Dexamethasone sodium phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2392−39−4 : Dexamethasone sodium phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23950−58−5 : Propyzamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 23950−58−5 : Propyzamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2396−68−1 : 4−tert−Butylbenzenethiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2396−68−1 : 4−tert−Butylbenzenethiol

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2409−55−4 : 2−tert−Butyl−4−methylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2409−55−4 : 2−tert−Butyl−4−methylphenol

Agonist: 0 Antagonist: 0.023

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24157−81−1 : 2,6−Diisopropylnaphthalene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24157−81−1 : 2,6−Diisopropylnaphthalene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24169−02−6 : Econazole nitrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24169−02−6 : Econazole nitrate

Agonist: 0 Antagonist: 0.05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2416−94−6 : 2,3,6−Trimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2416−94−6 : 2,3,6−Trimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2425−06−1 : Captafol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2425−06−1 : Captafol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2425−77−6 : 2−Hexyl−1−decanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2425−77−6 : 2−Hexyl−1−decanol

Agonist: 0.0032 Antagonist: 0.0081

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2426−08−6 : Butyl glycidyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2426−08−6 : Butyl glycidyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24307−26−4 : Mepiquat chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24307−26−4 : Mepiquat chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2432−87−3 : Dioctyl succinate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2432−87−3 : Dioctyl succinate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2433−14−9 : 4−Cyclohexylcyclohexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2433−14−9 : 4−Cyclohexylcyclohexanol

Agonist: 0.037 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2440−22−4 : 2−(2H−Benzotriazol−2−yl)−4−methylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2440−22−4 : 2−(2H−Benzotriazol−2−yl)−4−methylphenol

Agonist: 0.083 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2445−77−4 : 2−Methylbutyl isovalerate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2445−77−4 : 2−Methylbutyl isovalerate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2451−62−9 : Triglycidyl isocyanurate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2451−62−9 : Triglycidyl isocyanurate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24549−06−2 : 2−Ethyl−6−methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24549−06−2 : 2−Ethyl−6−methylaniline

Agonist: 0.0088 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2457−01−4 : Barium bis(2−ethylhexanoate)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2457−01−4 : Barium bis(2−ethylhexanoate)

Agonist: 0.024 Antagonist: 0.06

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24602−86−6 : Tridemorph

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24602−86−6 : Tridemorph

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2465−27−2 : Auramine hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2465−27−2 : Auramine hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2467−02−9 : Bisphenol F

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2467−02−9 : Bisphenol F

Agonist: 0.046 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24800−44−0 : Tripropylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24800−44−0 : Tripropylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24851−98−7 : Methyl dihydrojasmonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 24851−98−7 : Methyl dihydrojasmonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2491−38−5 : 2−Bromo−4−hydroxyacetophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2491−38−5 : 2−Bromo−4−hydroxyacetophenone

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2492−26−4 : Sodium 2−mercaptobenzothiolate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2492−26−4 : Sodium 2−mercaptobenzothiolate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 249296−43−3 : CJ−013610

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 249296−43−3 : CJ−013610

Agonist: 0 Antagonist: 0.055

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25057−89−0 : Bentazone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25057−89−0 : Bentazone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25155−18−4 : Methylbenzethonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25155−18−4 : Methylbenzethonium chloride

Agonist: 0.017 Antagonist: 0.11

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25155−30−0 : Sodium dodecylbenzenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25155−30−0 : Sodium dodecylbenzenesulfonate

Agonist: 0 Antagonist: 0.016

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25168−05−2 : Chlorotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25168−05−2 : Chlorotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25265−71−8 : Dipropylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25265−71−8 : Dipropylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2528−16−7 : Monobenzyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2528−16−7 : Monobenzyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25322−69−4 : Polypropylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25322−69−4 : Polypropylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 253450−09−8 : Besonprodil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 253450−09−8 : Besonprodil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25360−10−5 : tert−Nonanethiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25360−10−5 : tert−Nonanethiol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25496−72−4 : Glyceryl monooleate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25496−72−4 : Glyceryl monooleate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25498−49−1 : Tripropylene glycol monomethyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25498−49−1 : Tripropylene glycol monomethyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2550−40−5 : Dicyclohexyl disulfide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2550−40−5 : Dicyclohexyl disulfide

Agonist: 0.014 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2554−06−5 : 1,3,5,7−Tetramethyl−1,3,5,7−tetravinylcyclotetrasiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2554−06−5 : 1,3,5,7−Tetramethyl−1,3,5,7−tetravinylcyclotetrasiloxane

Agonist: 0.047 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25550−98−5 : Diisodecylphenyl phosphite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25550−98−5 : Diisodecylphenyl phosphite

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25606−41−1 : Propamocarb hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25606−41−1 : Propamocarb hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25638−17−9 : Butylnaphthalenesulfonic acid sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25638−17−9 : Butylnaphthalenesulfonic acid sodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25812−30−0 : Gemfibrozil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25812−30−0 : Gemfibrozil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2593−15−9 : Etridiazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2593−15−9 : Etridiazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25956−17−6 : Allura Red C.I.16035

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 25956−17−6 : Allura Red C.I.16035

Agonist: 0 Antagonist: 0.018

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26002−80−2 : Phenothrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26002−80−2 : Phenothrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26027−38−3 : Polyoxyethylene(10)nonylphenyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26027−38−3 : Polyoxyethylene(10)nonylphenyl ether

Agonist: 3e−05 Antagonist: 0.2

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26040−51−7 : Bis(2−ethylhexyl) tetrabromophthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26040−51−7 : Bis(2−ethylhexyl) tetrabromophthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2610−11−9 : C.I. Direct Red 81 disodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2610−11−9 : C.I. Direct Red 81 disodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26172−55−4 : 5−Chloro−2−methyl−3(2H)−isothiazolone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26172−55−4 : 5−Chloro−2−methyl−3(2H)−isothiazolone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 261947−38−0 : CP−532623

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 261947−38−0 : CP−532623

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26225−79−6 : Ethofumesate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26225−79−6 : Ethofumesate

Agonist: 0.0056 Antagonist: 0.0094

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 262376−75−0 : HMR1426

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 262376−75−0 : HMR1426

Agonist: 0.012 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26264−06−2 : Calcium dodecylbenzene sulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26264−06−2 : Calcium dodecylbenzene sulfonate

Agonist: 0 Antagonist: 0.035

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2627−95−4 : 1,3−Divinyl−1,1,3,3−tetramethyl disiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2627−95−4 : 1,3−Divinyl−1,1,3,3−tetramethyl disiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2634−33−5 : 1,2−Benzisothiazolin−3−one

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2634−33−5 : 1,2−Benzisothiazolin−3−one

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 263553−33−9 : GW473178E methyl benzene sulphonic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 263553−33−9 : GW473178E methyl benzene sulphonic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26402−26−6 : Glyceryl monooctanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26402−26−6 : Glyceryl monooctanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26447−10−9 : Ammonium xylene sulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26447−10−9 : Ammonium xylene sulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 264618−44−2 : SSR146977

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 264618−44−2 : SSR146977

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26530−20−1 : Octhilinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26530−20−1 : Octhilinone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26628−22−8 : Sodium azide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26628−22−8 : Sodium azide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26644−46−2 : Triforine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26644−46−2 : Triforine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2675−77−6 : Chloroneb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2675−77−6 : Chloroneb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2687−25−4 : 2,3−Diaminotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2687−25−4 : 2,3−Diaminotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2687−94−7 : N−Octyl−2−pyrrolidone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2687−94−7 : N−Octyl−2−pyrrolidone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2687−96−9 : 1−Dodecyl−2−pyrrolidinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2687−96−9 : 1−Dodecyl−2−pyrrolidinone

Agonist: 0 Antagonist: 0.00014

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26896−20−8 : Neodecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 26896−20−8 : Neodecanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2694−54−4 : Triprop−2−en−1−yl benzene−1,2,4−tricarboxylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2694−54−4 : Triprop−2−en−1−yl benzene−1,2,4−tricarboxylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2696−84−6 : 4−Propylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2696−84−6 : 4−Propylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2702−72−9 : 2,4−D sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2702−72−9 : 2,4−D sodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27090−63−7 : N,N,N',N'−Tetrabutyl−1,6−hexanediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27090−63−7 : N,N,N',N'−Tetrabutyl−1,6−hexanediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27138−31−4 : Di(propylene glycol) dibenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27138−31−4 : Di(propylene glycol) dibenzoate

Agonist: 0.018 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27176−87−0 : Dodecylbenzenesulfonic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27176−87−0 : Dodecylbenzenesulfonic acid

Agonist: 0.0019 Antagonist: 0.026

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27178−16−1 : Diisodecyl hexanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27178−16−1 : Diisodecyl hexanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 271−89−6 : 2,3−Benzofuran

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 271−89−6 : 2,3−Benzofuran

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27193−86−8 : Dodecylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27193−86−8 : Dodecylphenol

Agonist: 0.54 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27253−33−4 : Calcium neodecanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27253−33−4 : Calcium neodecanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27306−78−1 : Silwet L77

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27306−78−1 : Silwet L77

Agonist: 0.00012 Antagonist: 0.092

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27314−13−2 : Norflurazon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27314−13−2 : Norflurazon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27323−41−7 : Dodecylbenzene sulfonate triethanolamine (1:1)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27323−41−7 : Dodecylbenzene sulfonate triethanolamine (1:1)

Agonist: 0.0055 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27344−41−8 : Disodium 4,4'−bis(2−sulfostyryl)biphenyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27344−41−8 : Disodium 4,4'−bis(2−sulfostyryl)biphenyl

Agonist: 0.0051 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2756−56−1 : Isobornyl propanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2756−56−1 : Isobornyl propanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2761−24−2 : Triethoxypentylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2761−24−2 : Triethoxypentylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2772−45−4 : 2,4−Bis(1−methyl−1−phenylethyl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2772−45−4 : 2,4−Bis(1−methyl−1−phenylethyl)phenol

Agonist: 0.043 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2782−57−2 : Troclosene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2782−57−2 : Troclosene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2783−94−0 : FD&C Yellow 6

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2783−94−0 : FD&C Yellow 6

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2795−39−3 : PFOS−K

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2795−39−3 : PFOS−K

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27955−94−8 : 4,4',4−Ethane−1,1,1−triyltriphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 27955−94−8 : 4,4',4−Ethane−1,1,1−triyltriphenol

Agonist: 0.44 Antagonist: 0.038

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2807−30−9 : 2−Propoxyethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2807−30−9 : 2−Propoxyethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28159−98−0 : Cybutryne

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28159−98−0 : Cybutryne

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28249−77−6 : Thiobencarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28249−77−6 : Thiobencarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 283594−90−1 : Spiromesifen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 283594−90−1 : Spiromesifen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2835−95−2 : 5−Amino−2−methylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2835−95−2 : 5−Amino−2−methylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28434−00−6 : S−Bioallethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28434−00−6 : S−Bioallethrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28631−66−5 : C.I. Acid Blue 22

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28631−66−5 : C.I. Acid Blue 22

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2870−32−8 : C.I. Direct Yellow 12

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2870−32−8 : C.I. Direct Yellow 12

Agonist: 0 Antagonist: 0.00023

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28804−88−8 : Dimethylnaphthalene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 28804−88−8 : Dimethylnaphthalene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 288104−79−0 : Surinabant

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 288104−79−0 : Surinabant

Agonist: 0.038 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 288−32−4 : Imidazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 288−32−4 : Imidazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 288−88−0 : 1H−1,2,4−Triazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 288−88−0 : 1H−1,2,4−Triazole

Agonist: 0.00022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2893−78−9 : Sodium dichloroisocyanurate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2893−78−9 : Sodium dichloroisocyanurate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 289716−94−5 : CP−607366

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 289716−94−5 : CP−607366

Agonist: 0 Antagonist: 0.005

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 290352−28−2 : CP−634384

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 290352−28−2 : CP−634384

Agonist: 0.0052 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29091−21−2 : Prodiamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29091−21−2 : Prodiamine

Agonist: 0.015 Antagonist: 0.08

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29122−68−7 : Atenolol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29122−68−7 : Atenolol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 291305−06−1 : UK−373911

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 291305−06−1 : UK−373911

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2917−73−9 : Dibutyl nonanedioate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2917−73−9 : Dibutyl nonanedioate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2919−66−6 : Melengestrol acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2919−66−6 : Melengestrol acetate

Agonist: 0.098 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2921−88−2 : Chlorpyrifos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2921−88−2 : Chlorpyrifos

Agonist: 0.032 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29232−93−7 : Pirimiphos−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29232−93−7 : Pirimiphos−methyl

Agonist: 0.038 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2934−05−6 : 2,4−Diisopropylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2934−05−6 : 2,4−Diisopropylphenol

Agonist: 0.011 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29385−43−1 : Tolyltriazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29385−43−1 : Tolyltriazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29387−86−8 : Propylene glycol monobutyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29387−86−8 : Propylene glycol monobutyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29420−49−3 : PFBS−K

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29420−49−3 : PFBS−K

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2943−75−1 : Triethoxyoctylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2943−75−1 : Triethoxyoctylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29590−42−9 : Isooctyl acrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29590−42−9 : Isooctyl acrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2971−36−0 : 2,2−Bis(4−hydroxyphenyl)−1,1,1−trichloroethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2971−36−0 : 2,2−Bis(4−hydroxyphenyl)−1,1,1−trichloroethane

Agonist: 0 Antagonist: 0.14

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−00−0 : Methyl parathion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−00−0 : Methyl parathion

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−02−2 : Phorate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−02−2 : Phorate

Agonist: 0.02 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−04−4 : Disulfoton

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−04−4 : Disulfoton

Agonist: 0.027 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−07−7 : Bis(2−ethylhexyl) phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−07−7 : Bis(2−ethylhexyl) phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298198−52−4 : SSR180711

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298198−52−4 : SSR180711

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29836−26−8 : Octyl beta−D−glucopyranoside

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 29836−26−8 : Octyl beta−D−glucopyranoside

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−46−4 : Carbamazepine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 298−46−4 : Carbamazepine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2996−92−1 : Trimethoxyphenylsilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 2996−92−1 : Trimethoxyphenylsilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 300−76−5 : Naled

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 300−76−5 : Naled

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3025−30−7 : Ethyl (2E,4Z)−deca−2,4−dienoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3025−30−7 : Ethyl (2E,4Z)−deca−2,4−dienoate

Agonist: 0 Antagonist: 0.023

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3026−63−9 : Sodium tridecyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3026−63−9 : Sodium tridecyl sulfate

Agonist: 0 Antagonist: 0.015

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 302−79−4 : trans−Retinoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 302−79−4 : trans−Retinoic acid

Agonist: 1e−04 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3033−77−0 : N,N,N−Trimethyl(oxiran−2−yl)methanaminium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3033−77−0 : N,N,N−Trimethyl(oxiran−2−yl)methanaminium chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 30399−84−9 : Isooctadecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 30399−84−9 : Isooctadecanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 30516−87−1 : 3'−Azido−3'−deoxythymidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 30516−87−1 : 3'−Azido−3'−deoxythymidine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 30560−19−1 : Acephate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 30560−19−1 : Acephate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3056−17−5 : Stavudine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3056−17−5 : Stavudine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 307−24−4 : PFHxA

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 307−24−4 : PFHxA

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 309−00−2 : Aldrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 309−00−2 : Aldrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 311−45−5 : Paraoxon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 311−45−5 : Paraoxon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 31218−83−4 : Propetamphos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 31218−83−4 : Propetamphos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 313994−79−5 : MK−578

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 313994−79−5 : MK−578

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 314−40−9 : Bromacil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 314−40−9 : Bromacil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3147−75−9 : Octrizole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3147−75−9 : Octrizole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 31519−22−9 : 1,4−Dihydroxy−2−naphthoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 31519−22−9 : 1,4−Dihydroxy−2−naphthoic acid

Agonist: 0 Antagonist: 0.022

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3164−85−0 : Potassium 2−ethylhexanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3164−85−0 : Potassium 2−ethylhexanoate

Agonist: 0.0072 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3194−55−6 : 1,2,5,6,9,10−Hexabromocyclododecane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3194−55−6 : 1,2,5,6,9,10−Hexabromocyclododecane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 319−85−7 : beta−Hexachlorocyclohexane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 319−85−7 : beta−Hexachlorocyclohexane

Agonist: 0.067 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 32388−55−9 : 1−Cedr−8−en−9−ylethanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 32388−55−9 : 1−Cedr−8−en−9−ylethanone

Agonist: 0.097 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3268−49−3 : 3−(Methylthio)propanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3268−49−3 : 3−(Methylthio)propanal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 32809−16−8 : Procymidone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 32809−16−8 : Procymidone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 328−84−7 : 1,2−Dichloro−4−(trifluoromethyl)benzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 328−84−7 : 1,2−Dichloro−4−(trifluoromethyl)benzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3296−90−0 : 2,2−Bis(bromomethyl)−1,3−propanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3296−90−0 : 2,2−Bis(bromomethyl)−1,3−propanediol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 330198−91−9 : Fully acetylated glycerol monoester on 12−Hydroxystearic acid (85%); Fully acetylated glycerol monostearate represents (10%)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 330198−91−9 : Fully acetylated glycerol monoester on 12−Hydroxystearic acid (85%); Fully acetylated glycerol monostearate represents (10%)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 330−54−1 : Diuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 330−54−1 : Diuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 330−55−2 : Linuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 330−55−2 : Linuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33089−61−1 : Amitraz

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33089−61−1 : Amitraz

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 331623−06−4 : MK−547

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 331623−06−4 : MK−547

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3319−31−1 : Tris(2−ethylhexyl) trimellitate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3319−31−1 : Tris(2−ethylhexyl) trimellitate

Agonist: 0.16 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33228−44−3 : 4−Pentylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33228−44−3 : 4−Pentylaniline

Agonist: 0.029 Antagonist: 0.0046

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33228−45−4 : 4−Hexylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33228−45−4 : 4−Hexylaniline

Agonist: 0.015 Antagonist: 0.05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 333−41−5 : Diazinon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 333−41−5 : Diazinon

Agonist: 0.044 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3337−71−1 : Asulam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3337−71−1 : Asulam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 334−48−5 : Decanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 334−48−5 : Decanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 335−67−1 : PFOA

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 335−67−1 : PFOA

Agonist: 0 Antagonist: 2.9e−06

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 335−76−2 : PFDA

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 335−76−2 : PFDA

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33629−47−9 : Butralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33629−47−9 : Butralin

Agonist: 0.035 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33703−08−1 : Hexanedioic acid, diisononyl ester

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33703−08−1 : Hexanedioic acid, diisononyl ester

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3380−34−5 : Triclosan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3380−34−5 : Triclosan

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33820−53−0 : Isopropalin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33820−53−0 : Isopropalin

Agonist: 0.015 Antagonist: 0.041

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3383−96−8 : Temephos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3383−96−8 : Temephos

Agonist: 0.0025 Antagonist: 0.022

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3391−86−4 : 1−Octen−3−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3391−86−4 : 1−Octen−3−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33956−49−9 : Codlelure

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 33956−49−9 : Codlelure

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34014−18−1 : Tebuthiuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34014−18−1 : Tebuthiuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34256−82−1 : Acetochlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34256−82−1 : Acetochlor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34451−19−9 : Butyl (2S)−2−hydroxypropanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34451−19−9 : Butyl (2S)−2−hydroxypropanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 344930−95−6 : SSR69071

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 344930−95−6 : SSR69071

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3452−97−9 : 3,5,5−Trimethyl−1−hexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3452−97−9 : 3,5,5−Trimethyl−1−hexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34590−94−8 : Propanol, 1(or 2)−(2−methoxymethylethoxy)−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 34590−94−8 : Propanol, 1(or 2)−(2−methoxymethylethoxy)−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 349495−42−7 : PharmaGSID_47263

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 349495−42−7 : PharmaGSID_47263

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35256−85−0 : Butam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35256−85−0 : Butam

Agonist: 0.08 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 353280−07−6 : CP−612372

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 353280−07−6 : CP−612372

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35367−38−5 : Diflubenzuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35367−38−5 : Diflubenzuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35400−43−2 : Sulprofos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35400−43−2 : Sulprofos

Agonist: 0.028 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3547−33−9 : 2−Hydroxyethyl octyl sulfide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3547−33−9 : 2−Hydroxyethyl octyl sulfide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35554−44−0 : Imazalil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35554−44−0 : Imazalil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35575−96−3 : Azamethiphos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35575−96−3 : Azamethiphos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35691−65−7 : 1,2−Dibromo−2,4−dicyanobutane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 35691−65−7 : 1,2−Dibromo−2,4−dicyanobutane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 361343−19−3 : Elzasonan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 361343−19−3 : Elzasonan

Agonist: 0 Antagonist: 0.009

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 361377−29−9 : Fluoxastrobin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 361377−29−9 : Fluoxastrobin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3622−84−2 : N−Butylbenzenesulfonamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3622−84−2 : N−Butylbenzenesulfonamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3653−48−3 : MCPA−sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3653−48−3 : MCPA−sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 36631−30−8 : Triisodecyl trimellitate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 36631−30−8 : Triisodecyl trimellitate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 36653−82−4 : 1−Hexadecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 36653−82−4 : 1−Hexadecanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 36734−19−7 : Iprodione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 36734−19−7 : Iprodione

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3681−71−8 : (3Z)−3−Hexenyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3681−71−8 : (3Z)−3−Hexenyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 368832−42−2 : CP−728663

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 368832−42−2 : CP−728663

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3691−35−8 : Chlorophacinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3691−35−8 : Chlorophacinone

Agonist: 0 Antagonist: 0.031

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3734−33−6 : Denatonium benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3734−33−6 : Denatonium benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3734−67−6 : C.I. Acid Red 1

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3734−67−6 : C.I. Acid Red 1

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3739−38−6 : 3−Phenoxybenzoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3739−38−6 : 3−Phenoxybenzoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 375−85−9 : Perfluoroheptanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 375−85−9 : Perfluoroheptanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 375−95−1 : PFNA

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 375−95−1 : PFNA

Agonist: 0.007 Antagonist: 0.02

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 37764−25−3 : Dichlormid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 37764−25−3 : Dichlormid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3811−04−9 : Potassium chlorate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3811−04−9 : Potassium chlorate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3811−73−2 : Sodium (2−pyridylthio)−N−oxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3811−73−2 : Sodium (2−pyridylthio)−N−oxide

Agonist: 0 Antagonist: 0.019

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3825−26−1 : PFOA, ammonium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3825−26−1 : PFOA, ammonium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3844−45−9 : FD&C Blue No. 1

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3844−45−9 : FD&C Blue No. 1

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3855−32−1 : 2,6,10−Trimethyl−2,6,10−triazaundecane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3855−32−1 : 2,6,10−Trimethyl−2,6,10−triazaundecane

Agonist: 0.0049 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3871−99−6 : PFHS−K

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3871−99−6 : PFHS−K

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3913−02−8 : 2−Butyloctan−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3913−02−8 : 2−Butyloctan−1−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39236−46−9 : Imidazolidinyl urea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39236−46−9 : Imidazolidinyl urea

Agonist: 0.0052 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3926−62−3 : Sodium chloroacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 3926−62−3 : Sodium chloroacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39300−45−3 : Dinocap

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39300−45−3 : Dinocap

Agonist: 0 Antagonist: 0.046

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39515−41−8 : Fenpropathrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39515−41−8 : Fenpropathrin

Agonist: 0.0092 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39905−57−2 : 4−Hexyloxyaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 39905−57−2 : 4−Hexyloxyaniline

Agonist: 0.016 Antagonist: 0.003

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 402910−27−4 : UK−416244

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 402910−27−4 : UK−416244

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 40487−42−1 : Pendimethalin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 40487−42−1 : Pendimethalin

Agonist: 0.11 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 40649−36−3 : 4−Propylcyclohexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 40649−36−3 : 4−Propylcyclohexanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4065−45−6 : Sulisobenzone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4065−45−6 : Sulisobenzone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4098−71−9 : Isophorone diisocyanate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4098−71−9 : Isophorone diisocyanate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4107−98−6 : N,N−Diisopropylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4107−98−6 : N,N−Diisopropylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41198−08−7 : Profenofos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41198−08−7 : Profenofos

Agonist: 0.0074 Antagonist: 0.014

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4130−42−1 : 2,6−Di−tert−butyl−4−ethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4130−42−1 : 2,6−Di−tert−butyl−4−ethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41372−08−1 : Methyldopa sesquihydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41372−08−1 : Methyldopa sesquihydrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41372−20−7 : Apomorphine hydrochloride hydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41372−20−7 : Apomorphine hydrochloride hydrate

Agonist: 0.0071 Antagonist: 0.031

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41481−66−7 : 4,4'−Sulfonylbis[2−(prop−2−en−1−yl)phenol]

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 41481−66−7 : 4,4'−Sulfonylbis[2−(prop−2−en−1−yl)phenol]

Agonist: 0.02 Antagonist: 0.038

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4151−50−2 : Sulfluramid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4151−50−2 : Sulfluramid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4180−23−8 : (E)−Anethole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4180−23−8 : (E)−Anethole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 420−04−2 : Cyanamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 420−04−2 : Cyanamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 42509−80−8 : Isazofos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 42509−80−8 : Isazofos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 427−51−0 : Cyproterone acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 427−51−0 : Cyproterone acetate

Agonist: 0.00028 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 42874−03−3 : Oxyfluorfen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 42874−03−3 : Oxyfluorfen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4291−63−8 : Cladribine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4291−63−8 : Cladribine

Agonist: 0.016 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 43121−43−3 : Triadimefon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 43121−43−3 : Triadimefon

Agonist: 0.0095 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 43222−48−6 : Difenzoquat metilsulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 43222−48−6 : Difenzoquat metilsulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4342−36−3 : Tributyltin benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4342−36−3 : Tributyltin benzoate

Agonist: 0 Antagonist: 0.15

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4344−55−2 : 4−Butyloxyaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4344−55−2 : 4−Butyloxyaniline

Agonist: 0.011 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4376−18−5 : Monomethyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4376−18−5 : Monomethyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4376−20−9 : Mono(2−ethylhexyl) phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4376−20−9 : Mono(2−ethylhexyl) phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 439687−69−1 : Nelivaptan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 439687−69−1 : Nelivaptan

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4418−26−2 : Sodium dehydroacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4418−26−2 : Sodium dehydroacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4437−85−8 : Butylene carbonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4437−85−8 : Butylene carbonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 444610−91−7 : PharmaGSID_47315

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 444610−91−7 : PharmaGSID_47315

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4449−51−8 : Cyclopamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4449−51−8 : Cyclopamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 445295−04−5 : CP−671305

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 445295−04−5 : CP−671305

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4455−26−9 : N−Methyldioctylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4455−26−9 : N−Methyldioctylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 446−72−0 : Genistein

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 446−72−0 : Genistein

Agonist: 0.77 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4468−42−2 : 3−Phenylhexane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4468−42−2 : 3−Phenylhexane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 446−86−6 : Azathioprine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 446−86−6 : Azathioprine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 451−40−1 : 1,2−Diphenylethanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 451−40−1 : 1,2−Diphenylethanone

Agonist: 0.035 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4548−53−2 : FD&C Red 4

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4548−53−2 : FD&C Red 4

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4553−62−2 : 2−Methylpentanedinitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4553−62−2 : 2−Methylpentanedinitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4574−04−3 : Myristyltrimethylammonium chlorideN,N,N−Trimethyltetradecan−1−aminium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4574−04−3 : Myristyltrimethylammonium chlorideN,N,N−Trimethyltetradecan−1−aminium chloride

Agonist: 5.5e−05 Antagonist: 0.043

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 460−00−4 : 1−Bromo−4−fluorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 460−00−4 : 1−Bromo−4−fluorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4602−84−0 : Farnesol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4602−84−0 : Farnesol

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 461023−63−2 : Aplaviroc hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 461023−63−2 : Aplaviroc hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 461−58−5 : Cyanoguanidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 461−58−5 : Cyanoguanidine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 463−40−1 : Linolenic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 463−40−1 : Linolenic acid

Agonist: 0.0018 Antagonist: 0.0056

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4638−48−6 : 5−Chlorosalicylanilide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4638−48−6 : 5−Chlorosalicylanilide

Agonist: 0 Antagonist: 0.026

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 464−49−3 : D−Camphor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 464−49−3 : D−Camphor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4707−47−5 : Methyl 2,4−dihydroxy−3,6−dimethylbenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4707−47−5 : Methyl 2,4−dihydroxy−3,6−dimethylbenzoate

Agonist: 0.015 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 470−82−6 : 1,8−Cineol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 470−82−6 : 1,8−Cineol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4712−55−4 : Diphenyl phosphite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4712−55−4 : Diphenyl phosphite

Agonist: 0.16 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 473289−62−2 : Ilepatril

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 473289−62−2 : Ilepatril

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 474−86−2 : Equilin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 474−86−2 : Equilin

Agonist: 0.98 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 478149−53−0 : PHA−00543613

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 478149−53−0 : PHA−00543613

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 478263−98−8 : AVE3295

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 478263−98−8 : AVE3295

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 480−40−0 : Chrysin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 480−40−0 : Chrysin

Agonist: 0.16 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 480−63−7 : 2,4,6−Trimethylbenzoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 480−63−7 : 2,4,6−Trimethylbenzoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 484−17−3 : 9−Phenanthrol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 484−17−3 : 9−Phenanthrol

Agonist: 0 Antagonist: 0.031

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 486−56−6 : Cotinine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 486−56−6 : Cotinine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 486−66−8 : Daidzein

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 486−66−8 : Daidzein

Agonist: 0.62 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 487−06−9 : 5,7−Dimethoxy−2H−chromen−2−one

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 487−06−9 : 5,7−Dimethoxy−2H−chromen−2−one

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 489−01−0 : 2,6−Di−tert−butyl−4−methoxyphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 489−01−0 : 2,6−Di−tert−butyl−4−methoxyphenol

Agonist: 0.01 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4904−61−4 : 1,5,9−Cyclododecatriene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4904−61−4 : 1,5,9−Cyclododecatriene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 491−80−5 : Biochanin A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 491−80−5 : Biochanin A

Agonist: 0.47 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 493−52−7 : Methyl red

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 493−52−7 : Methyl red

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4940−11−8 : 2−Ethyl−3−hydroxy−4H−pyran−4−one

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 4940−11−8 : 2−Ethyl−3−hydroxy−4H−pyran−4−one

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 49562−28−9 : Fenofibrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 49562−28−9 : Fenofibrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 496−46−8 : Glycoluril

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 496−46−8 : Glycoluril

Agonist: 0.035 Antagonist: 0.088

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 496−72−0 : 3,4−Diaminotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 496−72−0 : 3,4−Diaminotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 499−75−2 : Isopropyl−o−cresol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 499−75−2 : Isopropyl−o−cresol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 499−83−2 : 2,6−Pyridinedicarboxylic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 499−83−2 : 2,6−Pyridinedicarboxylic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 500−38−9 : Nordihydroguaiaretic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 500−38−9 : Nordihydroguaiaretic acid

Agonist: 0.18 Antagonist: 0.046

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 501027−49−2 : PD−0333941

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 501027−49−2 : PD−0333941

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−14−6 : Ergocalciferol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−14−6 : Ergocalciferol

Agonist: 0 Antagonist: 0.024

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−21−5 : Lactic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−21−5 : Lactic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−22−6 : Corticosterone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−22−6 : Corticosterone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−27−1 : Estriol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−27−1 : Estriol

Agonist: 0.96 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−28−2 : 17beta−Estradiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−28−2 : 17beta−Estradiol

Agonist: 1 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−29−3 : p,p'−DDT

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−29−3 : p,p'−DDT

Agonist: 0.24 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−35−1 : Thalidomide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−35−1 : Thalidomide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−41−9 : Clomiphene citrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−41−9 : Clomiphene citrate

Agonist: 0.031 Antagonist: 0.82

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50471−44−8 : Vinclozolin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50471−44−8 : Vinclozolin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−55−5 : Reserpine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−55−5 : Reserpine

Agonist: 0 Antagonist: 8.2e−09

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50594−66−6 : Acifluorfen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50594−66−6 : Acifluorfen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−65−7 : Niclosamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−65−7 : Niclosamide

Agonist: 0 Antagonist: 0.00011

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−70−4 : D−Glucitol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−70−4 : D−Glucitol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−78−2 : Aspirin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−78−2 : Aspirin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−81−7 : L−Ascorbic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50−81−7 : L−Ascorbic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50892−23−4 : Pirinixic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 50892−23−4 : Pirinixic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 510−15−6 : Chlorobenzilate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 510−15−6 : Chlorobenzilate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−03−6 : Piperonyl butoxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−03−6 : Piperonyl butoxide

Agonist: 0.0065 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−05−8 : Procaine hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−05−8 : Procaine hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5116−94−9 : Monotridecyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5116−94−9 : Monotridecyl phosphate

Agonist: 0 Antagonist: 0.016

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−21−8 : 5−Fluorouracil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−21−8 : 5−Fluorouracil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51218−45−2 : Metolachlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51218−45−2 : Metolachlor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51229−78−8 : Chloroallyl methenamine chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51229−78−8 : Chloroallyl methenamine chloride

Agonist: 0.0024 Antagonist: 0.006

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51235−04−2 : Hexazinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51235−04−2 : Hexazinone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−24−1 : Tiratricol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−24−1 : Tiratricol

Agonist: 0.18 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 512−42−5 : Sodium methyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 512−42−5 : Sodium methyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 512−56−1 : Trimethyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 512−56−1 : Trimethyl phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−28−5 : 2,4−Dinitrophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−28−5 : 2,4−Dinitrophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−30−9 : Isoproterenol hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−30−9 : Isoproterenol hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51338−27−3 : Diclofop−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51338−27−3 : Diclofop−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5137−55−3 : Methyltrioctylammonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5137−55−3 : Methyltrioctylammonium chloride

Agonist: 0.0048 Antagonist: 0.04

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5138−18−1 : Sulfosuccinic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5138−18−1 : Sulfosuccinic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5146−66−7 : 2,6−Octadienenitrile, 3,7−dimethyl−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5146−66−7 : 2,6−Octadienenitrile, 3,7−dimethyl−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−52−5 : 6−Propyl−2−thiouracil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−52−5 : 6−Propyl−2−thiouracil

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5153−25−3 : 2−Ethylhexylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5153−25−3 : 2−Ethylhexylparaben

Agonist: 0.51 Antagonist: 0.006

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51580−86−0 : Sodium dichloro−s−triazinetrione dihydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51580−86−0 : Sodium dichloro−s−triazinetrione dihydrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51630−58−1 : Fenvalerate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51630−58−1 : Fenvalerate

Agonist: 0.0038 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51632−16−7 : 1−(Bromomethyl)−3−phenoxybenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51632−16−7 : 1−(Bromomethyl)−3−phenoxybenzene

Agonist: 0.082 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51707−55−2 : Thidiazuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51707−55−2 : Thidiazuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−79−6 : Urethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 51−79−6 : Urethane

Agonist: 0.0014 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−01−7 : Spironolactone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−01−7 : Spironolactone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 520−18−3 : Kaempferol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 520−18−3 : Kaempferol

Agonist: 0.34 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 520−36−5 : Apigenin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 520−36−5 : Apigenin

Agonist: 0.43 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 520−45−6 : Dehydroacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 520−45−6 : Dehydroacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 521−18−6 : 5alpha−Dihydrotestosterone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 521−18−6 : 5alpha−Dihydrotestosterone

Agonist: 0.5 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5216−25−1 : 4−Chlorobenzotrichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5216−25−1 : 4−Chlorobenzotrichloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52225−20−4 : dl−alpha−Tocopheryl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52225−20−4 : dl−alpha−Tocopheryl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52315−07−8 : Cypermethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52315−07−8 : Cypermethrin

Agonist: 0.0099 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5234−68−4 : Carboxin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5234−68−4 : Carboxin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−51−7 : Bronopol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−51−7 : Bronopol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 525−79−1 : Kinetin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 525−79−1 : Kinetin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 525−82−6 : Flavone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 525−82−6 : Flavone

Agonist: 0.034 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52645−53−1 : Permethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52645−53−1 : Permethrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 526−75−0 : 2,3−Dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 526−75−0 : 2,3−Dimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−68−6 : Trichlorfon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−68−6 : Trichlorfon

Agonist: 0.064 Antagonist: 0.0033

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 527−60−6 : 2,4,6−Trimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 527−60−6 : 2,4,6−Trimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 527680−56−4 : PHA−00568487

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 527680−56−4 : PHA−00568487

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52806−53−8 : Hydroxyflutamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52806−53−8 : Hydroxyflutamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 528−29−0 : 1,2−Dinitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 528−29−0 : 1,2−Dinitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−86−8 : Haloperidol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52−86−8 : Haloperidol

Agonist: 0.011 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52918−63−5 : Deltamethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 52918−63−5 : Deltamethrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−03−2 : Prednisone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−03−2 : Prednisone

Agonist: 0.059 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53112−28−0 : Pyrimethanil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53112−28−0 : Pyrimethanil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5315−79−7 : 1−Hydroxypyrene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5315−79−7 : 1−Hydroxypyrene

Agonist: 0.008 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−16−7 : Estrone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−16−7 : Estrone

Agonist: 0.99 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−19−0 : o,p'−DDD

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−19−0 : o,p'−DDD

Agonist: 0.32 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 532−02−5 : Sodium 2−naphthalenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 532−02−5 : Sodium 2−naphthalenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53219−21−9 : 7−Octen−2−ol, 2−methyl−6−methylene−, dihydro deriv.

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53219−21−9 : 7−Octen−2−ol, 2−methyl−6−methylene−, dihydro deriv.

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 532−27−4 : 2−Chloroacetophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 532−27−4 : 2−Chloroacetophenone

Agonist: 0.014 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 532−32−1 : Sodium benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 532−32−1 : Sodium benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5329−14−6 : Sulfamic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5329−14−6 : Sulfamic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 533−23−3 : 2,4−D−ethyl ester

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 533−23−3 : 2,4−D−ethyl ester

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5333−42−6 : 2−Octyl−1−dodecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5333−42−6 : 2−Octyl−1−dodecanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 533−74−4 : Dazomet

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 533−74−4 : Dazomet

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 534−13−4 : N,N'−Dimethylthiourea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 534−13−4 : N,N'−Dimethylthiourea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−43−0 : Dehydroepiandrosterone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−43−0 : Dehydroepiandrosterone

Agonist: 0.51 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 534−52−1 : 2−Methyl−4,6−dinitrophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 534−52−1 : 2−Methyl−4,6−dinitrophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5349−51−9 : 4−(2−Methylbutan−2−yl)cyclohexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5349−51−9 : 4−(2−Methylbutan−2−yl)cyclohexanol

Agonist: 0.26 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−70−3 : Dibenz(a,h)anthracene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−70−3 : Dibenz(a,h)anthracene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−86−1 : Indomethacin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53−86−1 : Indomethacin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53894−23−8 : Triisononyl trimellitate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53894−23−8 : Triisononyl trimellitate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5392−40−5 : 3,7−Dimethyl−2,6−octadienal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5392−40−5 : 3,7−Dimethyl−2,6−octadienal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53939−28−9 : (Z)−11−Hexadecenal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 53939−28−9 : (Z)−11−Hexadecenal

Agonist: 0.049 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5394−36−5 : 5−Ethyl−5−methylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5394−36−5 : 5−Ethyl−5−methylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 540−18−1 : Pentyl butyrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 540−18−1 : Pentyl butyrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5407−98−7 : Cyclobutyl phenyl ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5407−98−7 : Cyclobutyl phenyl ketone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 540−88−5 : tert−Butyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 540−88−5 : tert−Butyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 541−02−6 : Decamethylcyclopentasiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 541−02−6 : Decamethylcyclopentasiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54−11−5 : Nicotine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54−11−5 : Nicotine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 541−73−1 : 1,3−Dichlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 541−73−1 : 1,3−Dichlorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 542−92−7 : 1,3−Cyclopentadiene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 542−92−7 : 1,3−Cyclopentadiene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5437−45−6 : Benzyl bromoacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5437−45−6 : Benzyl bromoacetate

Agonist: 0.0014 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 544−63−8 : Tetradecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 544−63−8 : Tetradecanoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 544−76−3 : Hexadecane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 544−76−3 : Hexadecane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54593−83−8 : Chlorethoxyfos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54593−83−8 : Chlorethoxyfos

Agonist: 0.029 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54−62−6 : 4−Aminofolic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54−62−6 : 4−Aminofolic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54−85−3 : Isoniazid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54−85−3 : Isoniazid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 548−62−9 : Gentian Violet

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 548−62−9 : Gentian Violet

Agonist: 0 Antagonist: 5.3e−05

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54965−24−1 : Tamoxifen citrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 54965−24−1 : Tamoxifen citrate

Agonist: 0.019 Antagonist: 0.78

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 550−44−7 : N−Methylphthalimide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 550−44−7 : N−Methylphthalimide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55−18−5 : N−Nitrosodiethylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55−18−5 : N−Nitrosodiethylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55219−65−3 : Triadimenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55219−65−3 : Triadimenol

Agonist: 0.033 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 552−30−7 : Trimellitic anhydride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 552−30−7 : Trimellitic anhydride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55283−68−6 : Ethalfluralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55283−68−6 : Ethalfluralin

Agonist: 0.039 Antagonist: 9.7e−08

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55285−14−8 : Carbosulfan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55285−14−8 : Carbosulfan

Agonist: 0.01 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55290−64−7 : Dimethipin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55290−64−7 : Dimethipin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 553−26−4 : 4,4'−Bipyridine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 553−26−4 : 4,4'−Bipyridine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55335−06−3 : Triclopyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55335−06−3 : Triclopyr

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5536−61−8 : Sodium methacrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5536−61−8 : Sodium methacrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 553−70−8 : Magnesium dibenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 553−70−8 : Magnesium dibenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55−38−9 : Fenthion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55−38−9 : Fenthion

Agonist: 0.0072 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55406−53−6 : 3−Iodo−2−propynyl−N−butylcarbamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55406−53−6 : 3−Iodo−2−propynyl−N−butylcarbamate

Agonist: 0 Antagonist: 0.02

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55512−33−9 : Pyridate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55512−33−9 : Pyridate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55589−62−3 : Acesulfame potassium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55589−62−3 : Acesulfame potassium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 556−52−5 : Glycidol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 556−52−5 : Glycidol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 556−61−6 : Methyl isothiocyanate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 556−61−6 : Methyl isothiocyanate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 556−67−2 : Octamethylcyclotetrasiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 556−67−2 : Octamethylcyclotetrasiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55814−41−0 : Mepronil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55814−41−0 : Mepronil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55934−93−5 : Tripropylene glycol butyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55934−93−5 : Tripropylene glycol butyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55−98−1 : Busulfan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 55−98−1 : Busulfan

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5598−13−0 : Chlorpyrifos−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5598−13−0 : Chlorpyrifos−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5598−15−2 : Chlorpyrifos oxon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5598−15−2 : Chlorpyrifos oxon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−04−2 : 6−Methyl−2−thiouracil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−04−2 : 6−Methyl−2−thiouracil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 563−12−2 : Ethion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 563−12−2 : Ethion

Agonist: 0.14 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56375−79−2 : N,N−Dibutyl−N−methylbutan−1−aminium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56375−79−2 : N,N−Dibutyl−N−methylbutan−1−aminium chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−38−2 : Parathion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−38−2 : Parathion

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−53−1 : Diethylstilbestrol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−53−1 : Diethylstilbestrol

Agonist: 1 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−55−3 : Benz(a)anthracene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−55−3 : Benz(a)anthracene

Agonist: 0.043 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−72−4 : Coumaphos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−72−4 : Coumaphos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−81−5 : Glycerol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−81−5 : Glycerol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−95−1 : Chlorhexidine diacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 56−95−1 : Chlorhexidine diacetate

Agonist: 0.0023 Antagonist: 0.13

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5700−49−2 : 1,2−Ethanediamine dihydriodide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5700−49−2 : 1,2−Ethanediamine dihydriodide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−06−7 : Allyl isothiocyanate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−06−7 : Allyl isothiocyanate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−09−0 : Hexadecyltrimethylammonium bromide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−09−0 : Hexadecyltrimethylammonium bromide

Agonist: 4.7e−05 Antagonist: 0.1

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−10−3 : Hexadecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−10−3 : Hexadecanoic acid

Agonist: 0.0033 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−11−4 : Octadecanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−11−4 : Octadecanoic acid

Agonist: 0.19 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−13−6 : Urea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−13−6 : Urea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−14−7 : 1,1−Dimethylhydrazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−14−7 : 1,1−Dimethylhydrazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 571−58−4 : 1,4−Dimethylnaphthalene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 571−58−4 : 1,4−Dimethylnaphthalene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−30−7 : Phenobarbital sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−30−7 : Phenobarbital sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−41−0 : 5,5−Diphenylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−41−0 : 5,5−Diphenylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−50−1 : Sucrose

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−50−1 : Sucrose

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−55−6 : 1,2−Propylene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−55−6 : 1,2−Propylene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 576−26−1 : 2,6−Dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 576−26−1 : 2,6−Dimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−63−6 : 17alpha−Ethinylestradiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−63−6 : 17alpha−Ethinylestradiol

Agonist: 1 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 577−11−7 : Docusate sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 577−11−7 : Docusate sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−74−9 : Chlordane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−74−9 : Chlordane

Agonist: 0.033 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57754−85−5 : Clopyralid−olamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57754−85−5 : Clopyralid−olamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−83−0 : Progesterone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−83−0 : Progesterone

Agonist: 0.073 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57837−19−1 : Metalaxyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57837−19−1 : Metalaxyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−85−2 : Testosterone propionate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−85−2 : Testosterone propionate

Agonist: 0.41 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−91−0 : 17alpha−Estradiol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−91−0 : 17alpha−Estradiol

Agonist: 1 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 579−66−8 : 2,6−Diethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 579−66−8 : 2,6−Diethylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57966−95−7 : Cymoxanil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57966−95−7 : Cymoxanil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−97−6 : 7,12−Dimethylbenz(a)anthracene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 57−97−6 : 7,12−Dimethylbenz(a)anthracene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−08−2 : Caffeine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−08−2 : Caffeine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−14−0 : Pyrimethamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−14−0 : Pyrimethamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−18−4 : 17−Methyltestosterone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−18−4 : 17−Methyltestosterone

Agonist: 0.44 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 583−78−8 : 2,5−Dichlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 583−78−8 : 2,5−Dichlorophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58394−64−2 : Benzyloctyl adipate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58394−64−2 : Benzyloctyl adipate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 584−13−4 : 4−Amino−1,2,4−triazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 584−13−4 : 4−Amino−1,2,4−triazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58430−94−7 : 3,5,5−Trimethylhexyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58430−94−7 : 3,5,5−Trimethylhexyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 584−79−2 : Allethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 584−79−2 : Allethrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 584−84−9 : Toluene−2,4−diisocyanate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 584−84−9 : Toluene−2,4−diisocyanate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5850−86−2 : C.I. Acid Orange 8, monosodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5850−86−2 : C.I. Acid Orange 8, monosodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 585−34−2 : 3−tert−Butylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 585−34−2 : 3−tert−Butylphenol

Agonist: 0.035 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−55−9 : Theophylline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−55−9 : Theophylline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−56−0 : Pyridoxine hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−56−0 : Pyridoxine hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 586−62−9 : Terpinolene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 586−62−9 : Terpinolene

Agonist: 0.0059 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5870−93−9 : Heptyl butanoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5870−93−9 : Heptyl butanoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−72−0 : Triphenylethylene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−72−0 : Triphenylethylene

Agonist: 0.52 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 587−65−5 : 2−Chloro−N−phenylacetamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 587−65−5 : 2−Chloro−N−phenylacetamide

Agonist: 0 Antagonist: 0.005

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 587−85−9 : Diphenylmercury(II)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 587−85−9 : Diphenylmercury(II)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58846−77−8 : Decyl beta−D−glucopyranoside

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58846−77−8 : Decyl beta−D−glucopyranoside

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−85−5 : Biotin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−85−5 : Biotin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−86−6 : D−Xylose

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−86−6 : D−Xylose

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−89−9 : Lindane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−89−9 : Lindane

Agonist: 0.0076 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−93−5 : Hydrochlorothiazide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 58−93−5 : Hydrochlorothiazide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 589−68−4 : Tetradecanoic acid, 2,3−dihydroxypropyl ester

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 589−68−4 : Tetradecanoic acid, 2,3−dihydroxypropyl ester

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5902−51−2 : Terbacil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5902−51−2 : Terbacil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−05−2 : Methotrexate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−05−2 : Methotrexate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5915−41−3 : Terbuthylazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 5915−41−3 : Terbuthylazine

Agonist: 0.047 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59227−89−3 : Laurocapram

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59227−89−3 : Laurocapram

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−30−3 : Folic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−30−3 : Folic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−40−5 : Sulfaquinoxaline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−40−5 : Sulfaquinoxaline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 594−20−7 : 2,2−Dichloropropane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 594−20−7 : 2,2−Dichloropropane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−50−7 : 4−Chloro−3−methylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−50−7 : 4−Chloro−3−methylphenol

Agonist: 0.044 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59669−26−0 : Thiodicarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59669−26−0 : Thiodicarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−67−6 : Nicotinic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−67−6 : Nicotinic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59756−60−4 : Fluridone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59756−60−4 : Fluridone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 598−55−0 : Methyl carbamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 598−55−0 : Methyl carbamate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−87−0 : Nitrofurazone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 59−87−0 : Nitrofurazone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 599−64−4 : 4−Cumylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 599−64−4 : 4−Cumylphenol

Agonist: 0.54 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 599−79−1 : Sulfasalazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 599−79−1 : Sulfasalazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−09−3 : 4−Aminoazobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−09−3 : 4−Aminoazobenzene

Agonist: 0.1 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−12−8 : 2−Phenylethanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−12−8 : 2−Phenylethanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60168−88−9 : Fenarimol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60168−88−9 : Fenarimol

Agonist: 0.072 Antagonist: 0.0056

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 602−01−7 : 2,3−Dinitrotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 602−01−7 : 2,3−Dinitrotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60207−90−1 : Propiconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60207−90−1 : Propiconazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−33−3 : Linoleic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−33−3 : Linoleic acid

Agonist: 0 Antagonist: 0.027

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 603−35−0 : Triphenylphosphine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 603−35−0 : Triphenylphosphine

Agonist: 0.097 Antagonist: 0.00034

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−35−5 : Acetamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−35−5 : Acetamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 604−75−1 : Oxazepam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 604−75−1 : Oxazepam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−51−5 : Dimethoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−51−5 : Dimethoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 605−45−8 : Diisopropyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 605−45−8 : Diisopropyl phthalate

Agonist: 0.024 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−54−8 : Tetracycline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−54−8 : Tetracycline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6055−19−2 : Cyclophosphamide monohydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6055−19−2 : Cyclophosphamide monohydrate

Agonist: 0.079 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−56−0 : Methimazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−56−0 : Methimazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−57−1 : Dieldrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 60−57−1 : Dieldrin

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 606−20−2 : 2,6−Dinitrotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 606−20−2 : 2,6−Dinitrotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6088−51−3 : 6−Hydroxy−2−naphthyl disulfide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6088−51−3 : 6−Hydroxy−2−naphthyl disulfide

Agonist: 0.35 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 609−54−1 : 2,5−Dimethylbenzenesulfonic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 609−54−1 : 2,5−Dimethylbenzenesulfonic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 611−20−1 : Benzonitrile, 2−hydroxy−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 611−20−1 : Benzonitrile, 2−hydroxy−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 611−70−1 : Isopropyl phenyl ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 611−70−1 : Isopropyl phenyl ketone

Agonist: 0.00047 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 612−82−8 : 3,3'−Dimethylbenzidine dihydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 612−82−8 : 3,3'−Dimethylbenzidine dihydrochloride

Agonist: 0.12 Antagonist: 6.6e−05

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 614−45−9 : tert−Butyl perbenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 614−45−9 : tert−Butyl perbenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6149−03−7 : Sodium 4−octylbenzenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6149−03−7 : Sodium 4−octylbenzenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6152−33−6 : Sodium 2−phenylphenate tetrahydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6152−33−6 : Sodium 2−phenylphenate tetrahydrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6153−64−6 : Oxytetracycline dihydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6153−64−6 : Oxytetracycline dihydrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 616−45−5 : 2−Pyrrolidinone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 616−45−5 : 2−Pyrrolidinone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 61−73−4 : Methylene blue

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 61−73−4 : Methylene blue

Agonist: 0.0016 Antagonist: 0.078

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 61791−12−6 : Cremophor(R) EL

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 61791−12−6 : Cremophor(R) EL

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 61−82−5 : Amitrole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 61−82−5 : Amitrole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 618−45−1 : 3−Isopropylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 618−45−1 : 3−Isopropylphenol

Agonist: 0.015 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6190−65−4 : Deethylatrazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6190−65−4 : Deethylatrazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 620−17−7 : 3−Ethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 620−17−7 : 3−Ethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 621−64−7 : N−Nitrosodipropylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 621−64−7 : N−Nitrosodipropylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−23−7 : 4−Nitrobenzoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−23−7 : 4−Nitrobenzoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 622−97−9 : 4−Methylstyrene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 622−97−9 : 4−Methylstyrene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−38−4 : Phenylmercuric acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−38−4 : Phenylmercuric acetate

Agonist: 0 Antagonist: 0.11

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 625−55−8 : Isopropyl formate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 625−55−8 : Isopropyl formate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−56−6 : Thiourea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−56−6 : Thiourea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6259−76−3 : Hexyl salicylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6259−76−3 : Hexyl salicylate

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 626−43−7 : 3,5−Dichloroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 626−43−7 : 3,5−Dichloroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−73−7 : Dichlorvos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−73−7 : Dichlorvos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−74−8 : Sodium fluoroacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−74−8 : Sodium fluoroacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−75−9 : N−Nitrosodimethylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62−75−9 : N−Nitrosodimethylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 627−93−0 : Dimethyl adipate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 627−93−0 : Dimethyl adipate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6285−05−8 : Ethyl 4−chlorophenyl ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6285−05−8 : Ethyl 4−chlorophenyl ketone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 628−63−7 : Pentyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 628−63−7 : Pentyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62924−70−3 : Flumetralin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 62924−70−3 : Flumetralin

Agonist: 0.26 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 629−62−9 : Pentadecane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 629−62−9 : Pentadecane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 629−76−5 : 1−Pentadecanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 629−76−5 : 1−Pentadecanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 630−56−8 : Hydroxyprogesterone caproate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 630−56−8 : Hydroxyprogesterone caproate

Agonist: 0.033 Antagonist: 0.045

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63−05−8 : 4−Androstene−3,17−dione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63−05−8 : 4−Androstene−3,17−dione

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6317−18−6 : Methylene bis(thiocyanate)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6317−18−6 : Methylene bis(thiocyanate)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63−25−2 : Carbaryl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63−25−2 : Carbaryl

Agonist: 0.02 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 633−96−5 : C.I. Acid Orange 7

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 633−96−5 : C.I. Acid Orange 7

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63−42−3 : Lactose

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63−42−3 : Lactose

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6344−67−8 : 3−Hydroxyfluorene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6344−67−8 : 3−Hydroxyfluorene

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63449−41−2 : C8−18−Alkydimethylbenzyl ammonium chlorides

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63449−41−2 : C8−18−Alkydimethylbenzyl ammonium chlorides

Agonist: 0.041 Antagonist: 0.038

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6359−82−6 : Acid Yellow 11

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6359−82−6 : Acid Yellow 11

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6359−90−6 : C.I. Acid Yellow 34, monosodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6359−90−6 : C.I. Acid Yellow 34, monosodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6359−98−4 : C.I. Acid Yellow 17, disodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6359−98−4 : C.I. Acid Yellow 17, disodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63612−50−0 : Nilutamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 63612−50−0 : Nilutamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 636−21−5 : 2−Methylaniline hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 636−21−5 : 2−Methylaniline hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 637−07−0 : Clofibrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 637−07−0 : Clofibrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6381−77−7 : Sodium erythorbate (1:1)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6381−77−7 : Sodium erythorbate (1:1)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64−10−8 : Urea, phenyl−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64−10−8 : Urea, phenyl−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6422−86−2 : Bis(2−ethylhexyl) terephthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6422−86−2 : Bis(2−ethylhexyl) terephthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64359−81−5 : 4,5−Dichloro−2−octyl−3(2H)−isothiazolone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64359−81−5 : 4,5−Dichloro−2−octyl−3(2H)−isothiazolone

Agonist: 0.002 Antagonist: 0.046

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 643−79−8 : 1,2−Benzenedicarboxaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 643−79−8 : 1,2−Benzenedicarboxaldehyde

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 644−97−3 : Phenyl phosphorus dichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 644−97−3 : Phenyl phosphorus dichloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 645−56−7 : 4−Propylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 645−56−7 : 4−Propylphenol

Agonist: 0.036 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 645−62−5 : 2−Ethyl−2−hexenal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 645−62−5 : 2−Ethyl−2−hexenal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6459−94−5 : C.I. Acid Red 114

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6459−94−5 : C.I. Acid Red 114

Agonist: 0 Antagonist: 0.033

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64−67−5 : Diethyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64−67−5 : Diethyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64700−56−7 : Triclopyr−butotyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64700−56−7 : Triclopyr−butotyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 647−42−7 : 3,3,4,4,5,5,6,6,7,7,8,8,8−Tridecafluorooctan−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 647−42−7 : 3,3,4,4,5,5,6,6,7,7,8,8,8−Tridecafluorooctan−1−ol

Agonist: 0.006 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6485−40−1 : R−(−)−Carvone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6485−40−1 : R−(−)−Carvone

Agonist: 0.002 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64−86−8 : Colchicine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 64−86−8 : Colchicine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 648917−13−9 : AVE2865

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 648917−13−9 : AVE2865

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65−23−6 : Pyridoxine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65−23−6 : Pyridoxine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65277−42−1 : Ketoconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65277−42−1 : Ketoconazole

Agonist: 0 Antagonist: 0.013

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 654055−01−3 : Morin hydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 654055−01−3 : Morin hydrate

Agonist: 0.071 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65−45−2 : Salicylamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65−45−2 : Salicylamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 657−84−1 : Sodium 4−methylbenzenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 657−84−1 : Sodium 4−methylbenzenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65−85−0 : Benzoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 65−85−0 : Benzoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6610−29−3 : N−Methylhydrazinecarbothioamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6610−29−3 : N−Methylhydrazinecarbothioamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66215−27−8 : Cyromazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66215−27−8 : Cyromazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66230−04−4 : Esfenvalerate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66230−04−4 : Esfenvalerate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6624−73−3 : Pentane−1,5−diyl dibenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6624−73−3 : Pentane−1,5−diyl dibenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6625−46−3 : C.I. Acid Violet 12, disodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6625−46−3 : C.I. Acid Violet 12, disodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66−27−3 : Methyl methanesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66−27−3 : Methyl methanesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66332−96−5 : Flutolanil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66332−96−5 : Flutolanil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66357−35−5 : Ranitidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66357−35−5 : Ranitidine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66441−23−4 : Fenoxaprop−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66441−23−4 : Fenoxaprop−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66456−53−9 : Adipic acid, polypropyleneglycol, laurate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66456−53−9 : Adipic acid, polypropyleneglycol, laurate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66575−29−9 : Forskolin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66575−29−9 : Forskolin

Agonist: 0.029 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66−71−7 : 1,10−Phenanthroline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66−71−7 : 1,10−Phenanthroline

Agonist: 0 Antagonist: 0.00016

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66−81−9 : Cycloheximide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 66−81−9 : Cycloheximide

Agonist: 0 Antagonist: 0.12

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6683−19−8 : Irganox 1010

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6683−19−8 : Irganox 1010

Agonist: 0.11 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 668981−02−0 : CP−863187

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 668981−02−0 : CP−863187

Agonist: 0 Antagonist: 0.02

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6706−59−8 : L−Glucitol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6706−59−8 : L−Glucitol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67−20−9 : Nitrofurantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67−20−9 : Nitrofurantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6728−26−3 : (2E)−2−Hexenal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6728−26−3 : (2E)−2−Hexenal

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67−30−1 : Tetrac

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67−30−1 : Tetrac

Agonist: 9.4e−05 Antagonist: 0.03

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6734−80−1 : Metam−sodium hydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6734−80−1 : Metam−sodium hydrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67485−29−4 : Hydramethylnon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67485−29−4 : Hydramethylnon

Agonist: 0.15 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67564−91−4 : (2R,6S)−Fenpropimorph

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67564−91−4 : (2R,6S)−Fenpropimorph

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 676116−04−4 : PD 0343701

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 676116−04−4 : PD 0343701

Agonist: 0 Antagonist: 0.05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67−68−5 : Dimethyl sulfoxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67−68−5 : Dimethyl sulfoxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67747−09−5 : Prochloraz

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67747−09−5 : Prochloraz

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67786−14−5 : Acid Red 337

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 67786−14−5 : Acid Red 337

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 678−39−7 : 1,1,2,2−Tetrahydroperfluoro−1−decanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 678−39−7 : 1,1,2,2−Tetrahydroperfluoro−1−decanol

Agonist: 0.011 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6789−88−4 : Hexyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6789−88−4 : Hexyl benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−11−1 : Thioglycolic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−11−1 : Thioglycolic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−12−2 : N,N−Dimethylformamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−12−2 : N,N−Dimethylformamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68157−60−8 : Forchlorfenuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68157−60−8 : Forchlorfenuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68169−03−9 : 2−(Dihydrocyclopentadienyloxy)ethyl methacrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68169−03−9 : 2−(Dihydrocyclopentadienyloxy)ethyl methacrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 682−01−9 : Tetrapropyl orthosilicate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 682−01−9 : Tetrapropyl orthosilicate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−22−4 : Norethindrone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−22−4 : Norethindrone

Agonist: 0.67 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−26−8 : Retinol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−26−8 : Retinol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 683−18−1 : Dibutyltin dichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 683−18−1 : Dibutyltin dichloride

Agonist: 0 Antagonist: 0.18

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68359−37−5 : Cyfluthrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68359−37−5 : Cyfluthrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68392−35−8 : 4−Hydroxytamoxifen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68392−35−8 : 4−Hydroxytamoxifen

Agonist: 0.0032 Antagonist: 0.96

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6846−50−0 : 2,2,4−Trimethyl−1,3−pentanediol diisobutyrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6846−50−0 : 2,2,4−Trimethyl−1,3−pentanediol diisobutyrate

Agonist: 0.024 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 684−93−5 : N−Nitroso−N−methylurea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 684−93−5 : N−Nitroso−N−methylurea

Agonist: 0.0017 Antagonist: 0.0045

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68515−48−0 : DINP branched

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68515−48−0 : DINP branched

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68515−49−1 : 1,2−Benzenedicarboxylic acid, di−C9−11−branched alkyl esters, C10−rich

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68515−49−1 : 1,2−Benzenedicarboxylic acid, di−C9−11−branched alkyl esters, C10−rich

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68515−75−3 : Hexanedioic acid, di−C7−9−branched and linear alkyl esters

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68515−75−3 : Hexanedioic acid, di−C7−9−branched and linear alkyl esters

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68555−86−2 : Acid Orange 156

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68555−86−2 : Acid Orange 156

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68609−97−2 : C12−14−Alkyl glycidyl ether

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68609−97−2 : C12−14−Alkyl glycidyl ether

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68694−11−1 : Triflumizole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68694−11−1 : Triflumizole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68917−18−0 : Cornmint oil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68917−18−0 : Cornmint oil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6893−02−3 : 3,5,3'−Triiodothyronine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6893−02−3 : 3,5,3'−Triiodothyronine

Agonist: 0.12 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68959−20−6 : Disiquonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68959−20−6 : Disiquonium chloride

Agonist: 0.018 Antagonist: 0.0014

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−96−2 : 17alpha−Hydroxyprogesterone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 68−96−2 : 17alpha−Hydroxyprogesterone

Agonist: 0.22 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−09−0 : Chlorpromazine hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−09−0 : Chlorpromazine hydrochloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6915−15−7 : Malic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6915−15−7 : Malic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6923−22−4 : Monocrotophos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 6923−22−4 : Monocrotophos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 692−86−4 : Ethyl undec−10−enoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 692−86−4 : Ethyl undec−10−enoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69327−76−0 : Buprofezin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69327−76−0 : Buprofezin

Agonist: 0 Antagonist: 0.014

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69377−81−7 : Fluroxypyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69377−81−7 : Fluroxypyr

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 695−06−7 : gamma−Caprolactone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 695−06−7 : gamma−Caprolactone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69655−05−6 : 2',3'−Dideoxyinosine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69655−05−6 : 2',3'−Dideoxyinosine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−65−8 : D−Mannitol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−65−8 : D−Mannitol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−72−7 : Salicylic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−72−7 : Salicylic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−74−9 : Cytarabine hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69−74−9 : Cytarabine hydrochloride

Agonist: 0.025 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69806−40−2 : Haloxyfop−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69806−40−2 : Haloxyfop−methyl

Agonist: 0 Antagonist: 0.023

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69806−50−4 : Fluazifop−butyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 69806−50−4 : Fluazifop−butyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7011−83−8 : 2(3H)−Furanone, 5−hexyldihydro−5−methyl−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7011−83−8 : 2(3H)−Furanone, 5−hexyldihydro−5−methyl−

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 70−55−3 : 4−Toluenesulfonamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 70−55−3 : 4−Toluenesulfonamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 705−60−2 : (2−Nitro−1−propenyl)benzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 705−60−2 : (2−Nitro−1−propenyl)benzene

Agonist: 0 Antagonist: 0.019

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 70568−60−4 : 4−Butylcyclohexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 70568−60−4 : 4−Butylcyclohexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 706−14−9 : gamma−Decanolactone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 706−14−9 : gamma−Decanolactone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7080−50−4 : Chloramine−T trihydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7080−50−4 : Chloramine−T trihydrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 709−98−8 : Propanil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 709−98−8 : Propanil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71−23−8 : 1−Propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71−23−8 : 1−Propanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 712−50−5 : Cyclohexylphenylketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 712−50−5 : Cyclohexylphenylketone

Agonist: 0.038 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71283−80−2 : Fenoxaprop−P−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71283−80−2 : Fenoxaprop−P−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71526−07−3 : MON−4660

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71526−07−3 : MON−4660

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7173−51−5 : Didecyldimethylammonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7173−51−5 : Didecyldimethylammonium chloride

Agonist: 0.0032 Antagonist: 0.09

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71751−41−2 : Abamectin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 71751−41−2 : Abamectin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 717−74−8 : 1,3,5−Triisopropylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 717−74−8 : 1,3,5−Triisopropylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7212−44−4 : Nerolidol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7212−44−4 : Nerolidol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72178−02−0 : Fomesafen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72178−02−0 : Fomesafen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−20−8 : Endrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−20−8 : Endrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−33−3 : Mestranol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−33−3 : Mestranol

Agonist: 0.91 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−43−5 : Methoxychlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−43−5 : Methoxychlor

Agonist: 0.38 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72490−01−8 : Fenoxycarb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72490−01−8 : Fenoxycarb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 725228−45−5 : AVE5638

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 725228−45−5 : AVE5638

Agonist: 0.0091 Antagonist: 0.0071

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−54−8 : p,p'−DDD

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−54−8 : p,p'−DDD

Agonist: 0.075 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−55−9 : p,p'−DDE

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 72−55−9 : p,p'−DDE

Agonist: 0.11 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7287−19−6 : Prometryn

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7287−19−6 : Prometryn

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 732−11−6 : Phosmet

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 732−11−6 : Phosmet

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 73−22−3 : l−Tryptophan

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 73−22−3 : l−Tryptophan

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 732−26−3 : 2,4,6−Tris(tert−butyl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 732−26−3 : 2,4,6−Tris(tert−butyl)phenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 73−31−4 : Melatonin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 73−31−4 : Melatonin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7378−99−6 : N,N−Dimethyloctylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7378−99−6 : N,N−Dimethyloctylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7398−69−8 : Dimethyldiallylammonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7398−69−8 : Dimethyldiallylammonium chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 74051−80−2 : Sethoxydim

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 74051−80−2 : Sethoxydim

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 74115−24−5 : Clofentezine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 74115−24−5 : Clofentezine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 741−58−2 : Bensulide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 741−58−2 : Bensulide

Agonist: 0 Antagonist: 0.0087

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 742693−38−5 : SSR504734

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 742693−38−5 : SSR504734

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 744−45−6 : Diphenyl isophthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 744−45−6 : Diphenyl isophthalate

Agonist: 0.029 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7487−94−7 : Mercuric chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7487−94−7 : Mercuric chloride

Agonist: 0 Antagonist: 0.0051

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75330−75−5 : Lovastatin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75330−75−5 : Lovastatin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 753−73−1 : Dimethyltin dichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 753−73−1 : Dimethyltin dichloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7540−51−4 : (S)−(−)−beta−Citronellol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7540−51−4 : (S)−(−)−beta−Citronellol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 754−91−6 : PFOSA

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 754−91−6 : PFOSA

Agonist: 0.056 Antagonist: 0.033

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−50−3 : Trimethylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−50−3 : Trimethylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−60−5 : Dimethylarsinic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−60−5 : Dimethylarsinic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−64−9 : tert−Butylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−64−9 : tert−Butylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 756−79−6 : Dimethyl methylphosphonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 756−79−6 : Dimethyl methylphosphonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−86−5 : 2−Hydroxy−2−methylpropanenitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−86−5 : 2−Hydroxy−2−methylpropanenitrile

Agonist: 0.0035 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−99−0 : Dalapon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 75−99−0 : Dalapon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 759−94−4 : EPTC

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 759−94−4 : EPTC

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 760−23−6 : 3,4−Dichloro−1−butene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 760−23−6 : 3,4−Dichloro−1−butene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−03−9 : Trichloroacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−03−9 : Trichloroacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 762−04−9 : Diethyl phosphite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 762−04−9 : Diethyl phosphite

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7632−00−0 : Sodium nitrite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7632−00−0 : Sodium nitrite

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−44−8 : Heptachlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−44−8 : Heptachlor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−49−3 : Bornyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−49−3 : Bornyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76578−14−8 : Quizalofop−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76578−14−8 : Quizalofop−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7659−86−1 : 2−Ethylhexyl sulfanylacetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7659−86−1 : 2−Ethylhexyl sulfanylacetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7664−38−2 : Phosphoric acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7664−38−2 : Phosphoric acid

Agonist: 0.0074 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76738−62−0 : Paclobutrazol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76738−62−0 : Paclobutrazol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7681−76−7 : Ronidazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7681−76−7 : Ronidazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7681−82−5 : Sodium iodide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7681−82−5 : Sodium iodide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−87−9 : Triphenyltin hydroxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 76−87−9 : Triphenyltin hydroxide

Agonist: 0 Antagonist: 0.00041

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7696−12−0 : Tetramethrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7696−12−0 : Tetramethrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 769−92−6 : 4−tert−Butylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 769−92−6 : 4−tert−Butylaniline

Agonist: 0.0037 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 770−35−4 : 1−Phenoxy−2−propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 770−35−4 : 1−Phenoxy−2−propanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−06−5 : Gibberellic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−06−5 : Gibberellic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−09−8 : Phenolphthalein

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−09−8 : Phenolphthalein

Agonist: 0.36 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−40−7 : Bisphenol B

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−40−7 : Bisphenol B

Agonist: 0.75 Antagonist: 0.0031

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7747−35−5 : 5−Ethyl−1−aza−3,7−dioxabicyclo[3.3.0]octane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7747−35−5 : 5−Ethyl−1−aza−3,7−dioxabicyclo[3.3.0]octane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−47−4 : Hexachlorocyclopentadiene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−47−4 : Hexachlorocyclopentadiene

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−48−5 : 1,3−Dibromo−5,5−dimethylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−48−5 : 1,3−Dibromo−5,5−dimethylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77501−63−4 : Lactofen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77501−63−4 : Lactofen

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7757−79−1 : Potassium nitrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7757−79−1 : Potassium nitrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−71−4 : 5,5−Dimethylhydantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−71−4 : 5,5−Dimethylhydantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7773−06−0 : Ammonium sulfamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7773−06−0 : Ammonium sulfamate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−73−6 : Dicyclopentadiene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−73−6 : Dicyclopentadiene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7775−27−1 : Sodium persulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7775−27−1 : Sodium persulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−78−1 : Dimethyl sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−78−1 : Dimethyl sulfate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7779−27−3 : 1,3,5−Triethylhexahydro−s−triazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7779−27−3 : 1,3,5−Triethylhexahydro−s−triazine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−83−8 : Ethyl methylphenylglycidate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−83−8 : Ethyl methylphenylglycidate

Agonist: 0.0064 Antagonist: 0.016

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7785−26−4 : (−)−alpha−Pinene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7785−26−4 : (−)−alpha−Pinene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−86−1 : Tromethamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−86−1 : Tromethamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7786−34−7 : Mevinphos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 7786−34−7 : Mevinphos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−90−7 : Acetyl tributyl citrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−90−7 : Acetyl tributyl citrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−92−9 : Citric acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−92−9 : Citric acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−93−0 : Triethyl citrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 77−93−0 : Triethyl citrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−07−9 : Ethyltriethoxysilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−07−9 : Ethyltriethoxysilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−11−5 : Pentaerythritol tetranitrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−11−5 : Pentaerythritol tetranitrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−40−0 : Triethyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−40−0 : Triethyl phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−42−2 : Tris(2−ethylhexyl) phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−42−2 : Tris(2−ethylhexyl) phosphate

Agonist: 0.0046 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78473−71−9 : Enterolactone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78473−71−9 : Enterolactone

Agonist: 0.1 Antagonist: 8.8e−05

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−48−8 : Tribufos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−48−8 : Tribufos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78491−02−8 : Diazolidinyl urea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78491−02−8 : Diazolidinyl urea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−51−3 : Tris(2−butoxyethyl) phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−51−3 : Tris(2−butoxyethyl) phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78587−05−0 : Hexythiazox

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78587−05−0 : Hexythiazox

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−59−1 : Isophorone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−59−1 : Isophorone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−63−7 : 2,5−Dimethyl−2,5−di−(tert−butylperoxy)hexane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−63−7 : 2,5−Dimethyl−2,5−di−(tert−butylperoxy)hexane

Agonist: 0.013 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−69−3 : 3,7−Dimethyl−3−octanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−69−3 : 3,7−Dimethyl−3−octanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−70−6 : Linalool

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−70−6 : Linalool

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−82−0 : 2−Methylpropanenitrile

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−82−0 : 2−Methylpropanenitrile

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 789−02−6 : o,p'−DDT

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 789−02−6 : o,p'−DDT

Agonist: 0.49 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−96−6 : 1−Amino−2−propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 78−96−6 : 1−Amino−2−propanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−06−1 : Acrylamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−06−1 : Acrylamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79098−20−7 : 4−Chloropentylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79098−20−7 : 4−Chloropentylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−14−1 : Glycolic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−14−1 : Glycolic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−16−3 : N−Methylacetamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−16−3 : N−Methylacetamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79241−46−6 : Fluazifop−P−butyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79241−46−6 : Fluazifop−P−butyl

Agonist: 0.023 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−24−3 : Nitroethane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−24−3 : Nitroethane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79277−27−3 : Thifensulfuron−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79277−27−3 : Thifensulfuron−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−39−0 : Methacrylamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−39−0 : Methacrylamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−43−6 : Dichloroacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−43−6 : Dichloroacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−44−7 : Dimethylcarbamoyl chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−44−7 : Dimethylcarbamoyl chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79538−32−2 : Tefluthrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79538−32−2 : Tefluthrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−57−2 : Oxytetracycline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−57−2 : Oxytetracycline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79622−59−6 : Fluazinam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79622−59−6 : Fluazinam

Agonist: 0 Antagonist: 0.0077

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 797−63−7 : Norgestrel

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 797−63−7 : Norgestrel

Agonist: 0.43 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79902−63−9 : Simvastatin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79902−63−9 : Simvastatin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−92−5 : 2,2−Dimethyl−3−methylenebicyclo[2.2.1]heptane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−92−5 : 2,2−Dimethyl−3−methylenebicyclo[2.2.1]heptane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−94−7 : 3,3',5,5'−Tetrabromobisphenol A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−94−7 : 3,3',5,5'−Tetrabromobisphenol A

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−95−8 : 2,2',6,6'−Tetrachlorobisphenol A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79−95−8 : 2,2',6,6'−Tetrachlorobisphenol A

Agonist: 0.24 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79983−71−4 : Hexaconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 79983−71−4 : Hexaconazole

Agonist: 0.00014 Antagonist: 0.0061

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8000−34−8 : Clove leaf oil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8000−34−8 : Clove leaf oil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8000−41−7 : Terpineol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8000−41−7 : Terpineol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8001−54−5 : Benzalkonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8001−54−5 : Benzalkonium chloride

Agonist: 0 Antagonist: 0.06

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8004−92−0 : C.I. Acid Yellow 3 disodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8004−92−0 : C.I. Acid Yellow 3 disodium salt

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−05−7 : Bisphenol A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−05−7 : Bisphenol A

Agonist: 0.65 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8006−90−4 : Peppermint oil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8006−90−4 : Peppermint oil

Agonist: 0.0073 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8007−70−3 : Anise oil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8007−70−3 : Anise oil

Agonist: 0.055 Antagonist: 0.0034

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−07−9 : 4,4'−Dichlorodiphenyl sulfone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−07−9 : 4,4'−Dichlorodiphenyl sulfone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−08−0 : Dapsone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−08−0 : Dapsone

Agonist: 0.0016 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−09−1 : 4,4'−Sulfonyldiphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−09−1 : 4,4'−Sulfonyldiphenol

Agonist: 0.32 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−15−9 : Cumene hydroperoxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−15−9 : Cumene hydroperoxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8018−01−7 : Mancozeb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 8018−01−7 : Mancozeb

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−26−2 : alpha−Terpinyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−26−2 : alpha−Terpinyl acetate

Agonist: 0.0086 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−27−3 : Terpinyl propionate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−27−3 : Terpinyl propionate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−43−3 : Dicumyl peroxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−43−3 : Dicumyl peroxide

Agonist: 0.29 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−46−6 : 4−(2−Methylbutan−2−yl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−46−6 : 4−(2−Methylbutan−2−yl)phenol

Agonist: 0.4 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−54−6 : 3−(4−tert−Butylphenyl)−2−methylpropanal

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−54−6 : 3−(4−tert−Butylphenyl)−2−methylpropanal

Agonist: 0.0056 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−56−8 : alpha−Pinene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80−56−8 : alpha−Pinene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80844−07−1 : Etofenprox

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 80844−07−1 : Etofenprox

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−07−2 : Saccharin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−07−2 : Saccharin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81131−70−6 : Pravastatin sodium

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81131−70−6 : Pravastatin sodium

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81334−34−1 : Imazapyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81334−34−1 : Imazapyr

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81335−37−7 : Imazaquin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81335−37−7 : Imazaquin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81335−77−5 : Imazethapyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81335−77−5 : Imazethapyr

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81405−85−8 : Imazmethabenz

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81405−85−8 : Imazmethabenz

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81406−37−3 : Fluroxypyr−meptyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81406−37−3 : Fluroxypyr−meptyl

Agonist: 0.012 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81741−28−8 : Tributyltetradecylphosphonium chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81741−28−8 : Tributyltetradecylphosphonium chloride

Agonist: 0.04 Antagonist: 0.061

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81777−89−1 : Clomazone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81777−89−1 : Clomazone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−81−2 : Warfarin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−81−2 : Warfarin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 818−61−1 : 2−Hydroxyethyl acrylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 818−61−1 : 2−Hydroxyethyl acrylate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−88−9 : Rhodamine B

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−88−9 : Rhodamine B

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−90−3 : Phenolphthalin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 81−90−3 : Phenolphthalin

Agonist: 0.043 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 822−06−0 : 1,6−Diisocyanatohexane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 822−06−0 : 1,6−Diisocyanatohexane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82385−42−0 : Sodium saccharin hydrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82385−42−0 : Sodium saccharin hydrate

Agonist: 0.021 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 824−39−5 : Sodium 2−nitrophenolate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 824−39−5 : Sodium 2−nitrophenolate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82469−79−2 : Butyryl trihexyl citrate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82469−79−2 : Butyryl trihexyl citrate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 824−78−2 : Sodium 4−nitrophenolate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 824−78−2 : Sodium 4−nitrophenolate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82558−50−7 : Isoxaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82558−50−7 : Isoxaben

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82640−04−8 : Raloxifene hydrochloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82640−04−8 : Raloxifene hydrochloride

Agonist: 0 Antagonist: 0.97

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82657−04−3 : Bifenthrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82657−04−3 : Bifenthrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 826−62−0 : 3a,4,7,7a−Tetrahydro−4,7−methanoisobenzofuran−1,3−dione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 826−62−0 : 3a,4,7,7a−Tetrahydro−4,7−methanoisobenzofuran−1,3−dione

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82−68−8 : Pentachloronitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 82−68−8 : Pentachloronitrobenzene

Agonist: 0.0036 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 827−19−0 : Sodium 2,5−dimethylbenzenesulfonate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 827−19−0 : Sodium 2,5−dimethylbenzenesulfonate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 827−21−4 : Benzenesulfonic acid, 2,4−dimethyl−, sodium salt

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 827−21−4 : Benzenesulfonic acid, 2,4−dimethyl−, sodium salt

Agonist: 0.021 Antagonist: 0.052

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 828−00−2 : Dimethoxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 828−00−2 : Dimethoxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−32−9 : Acenaphthene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−32−9 : Acenaphthene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−41−0 : 1,2−Dimethyl−3−nitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−41−0 : 1,2−Dimethyl−3−nitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 834−12−8 : Ametryn

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 834−12−8 : Ametryn

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83657−24−3 : Diniconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83657−24−3 : Diniconazole

Agonist: 0 Antagonist: 0.0071

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−67−0 : Theobromine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−67−0 : Theobromine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−79−4 : Rotenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−79−4 : Rotenone

Agonist: 9.8e−05 Antagonist: 0.00011

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83834−59−7 : 2−Ethylhexyl trans−4−methoxycinnamate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83834−59−7 : 2−Ethylhexyl trans−4−methoxycinnamate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−88−5 : Riboflavin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 83−88−5 : Riboflavin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 838−85−7 : Diphenyl phosphate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 838−85−7 : Diphenyl phosphate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 838−88−0 : 4,4'−Methylenebis(2−methylaniline)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 838−88−0 : 4,4'−Methylenebis(2−methylaniline)

Agonist: 0.066 Antagonist: 0.01

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84087−01−4 : Quinclorac

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84087−01−4 : Quinclorac

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−16−2 : meso−Hexestrol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−16−2 : meso−Hexestrol

Agonist: 1 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 842−07−9 : C.I. Solvent Yellow 14

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 842−07−9 : C.I. Solvent Yellow 14

Agonist: 0.065 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84371−65−3 : Mifepristone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84371−65−3 : Mifepristone

Agonist: 0.0073 Antagonist: 0.46

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−61−7 : Dicyclohexyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−61−7 : Dicyclohexyl phthalate

Agonist: 0.029 Antagonist: 0.024

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−66−2 : Diethyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−66−2 : Diethyl phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−69−5 : Diisobutyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−69−5 : Diisobutyl phthalate

Agonist: 0.05 Antagonist: 0.068

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−74−2 : Dibutyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−74−2 : Dibutyl phthalate

Agonist: 0.041 Antagonist: 0.069

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−75−3 : Dihexyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84−75−3 : Dihexyl phthalate

Agonist: 0.021 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84852−15−3 : 4−Nonylphenol, branched

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 84852−15−3 : 4−Nonylphenol, branched

Agonist: 0.6 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−01−8 : Phenanthrene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−01−8 : Phenanthrene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 851916−42−2 : MK−812

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 851916−42−2 : MK−812

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85264−33−1 : (3,5−Dimethyl−1H−pyrazol−1−yl)methanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85264−33−1 : (3,5−Dimethyl−1H−pyrazol−1−yl)methanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−40−5 : 1,2,3,6−Tetrahydrophthalimide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−40−5 : 1,2,3,6−Tetrahydrophthalimide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−41−6 : Phthalimide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−41−6 : Phthalimide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85507−79−5 : Phthalic acid, diundecyl ester, branched and linear

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85507−79−5 : Phthalic acid, diundecyl ester, branched and linear

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85509−19−9 : Flusilazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85509−19−9 : Flusilazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85532−75−8 : PK 11195

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85532−75−8 : PK 11195

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−68−7 : Butyl benzyl phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 85−68−7 : Butyl benzyl phthalate

Agonist: 0.25 Antagonist: 0.001

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 860−22−0 : C.I. Acid Blue 74

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 860−22−0 : C.I. Acid Blue 74

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 862243−29−6 : AVE9423

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 862243−29−6 : AVE9423

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−30−6 : N−Nitrosodiphenylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−30−6 : N−Nitrosodiphenylamine

Agonist: 0.026 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86386−73−4 : Fluconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86386−73−4 : Fluconazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 864283−48−7 : GSK232420A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 864283−48−7 : GSK232420A

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86479−06−3 : Hexaflumuron

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86479−06−3 : Hexaflumuron

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−50−0 : Azinphos−methyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−50−0 : Azinphos−methyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−73−7 : Fluorene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−73−7 : Fluorene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−87−3 : 1−Naphthaleneacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 86−87−3 : 1−Naphthaleneacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 868−85−9 : Dimethyl hydrogen phosphite

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 868−85−9 : Dimethyl hydrogen phosphite

Agonist: 0.026 Antagonist: 0.066

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−01−4 : 7−(Dimethylamino)−4−methylcoumarin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−01−4 : 7−(Dimethylamino)−4−methylcoumarin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−18−3 : 4−tert−Butylphenyl salicylate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−18−3 : 4−tert−Butylphenyl salicylate

Agonist: 0.076 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−24−1 : Ethyl 2−methylbenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−24−1 : Ethyl 2−methylbenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 872−50−4 : N−Methyl−2−pyrrolidone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 872−50−4 : N−Methyl−2−pyrrolidone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−25−2 : Ethyl anthranilate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−25−2 : Ethyl anthranilate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87392−12−9 : S−Metolachlor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87392−12−9 : S−Metolachlor

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87546−18−7 : Flumiclorac−pentyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87546−18−7 : Flumiclorac−pentyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−61−6 : 1,2,3−Trichlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−61−6 : 1,2,3−Trichlorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−62−7 : 2,6−Dimethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−62−7 : 2,6−Dimethylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87674−68−8 : Dimethenamid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87674−68−8 : Dimethenamid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−68−3 : Hexachloro−1,3−butadiene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−68−3 : Hexachloro−1,3−butadiene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−69−4 : L−Tartaric acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−69−4 : L−Tartaric acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 877−24−7 : Monopotassium phthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 877−24−7 : Monopotassium phthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87818−31−3 : Cinmethylin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87818−31−3 : Cinmethylin

Agonist: 0.028 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87820−88−0 : Tralkoxydim

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87820−88−0 : Tralkoxydim

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−86−5 : Pentachlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−86−5 : Pentachlorophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−90−1 : Symclosene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 87−90−1 : Symclosene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−04−0 : 4−Chloro−3,5−dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−04−0 : 4−Chloro−3,5−dimethylphenol

Agonist: 0.063 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−06−2 : 2,4,6−Trichlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−06−2 : 2,4,6−Trichlorophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−12−0 : N−Vinyl−2−pyrrolidone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−12−0 : N−Vinyl−2−pyrrolidone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−18−6 : 2−tert−Butylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−18−6 : 2−tert−Butylphenol

Agonist: 0.009 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−24−4 : 2,2'−Methylenebis(ethyl−6−tert−butylphenol)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−24−4 : 2,2'−Methylenebis(ethyl−6−tert−butylphenol)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−30−2 : 3−Trifluoromethyl−4−nitrophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−30−2 : 3−Trifluoromethyl−4−nitrophenol

Agonist: 0.0095 Antagonist: 0.038

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−41−5 : 2−tert−Butylcyclohexyl acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−41−5 : 2−tert−Butylcyclohexyl acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−58−4 : 2,5−Di−tert−butylbenzene−1,4−diol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−58−4 : 2,5−Di−tert−butylbenzene−1,4−diol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−60−8 : 2−tert−Butyl−5−methylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−60−8 : 2−tert−Butyl−5−methylphenol

Agonist: 0.057 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88671−89−0 : Myclobutanil

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88671−89−0 : Myclobutanil

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−69−7 : 2−Isopropylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−69−7 : 2−Isopropylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−72−2 : 2−Nitrotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−72−2 : 2−Nitrotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−74−4 : 2−Nitroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−74−4 : 2−Nitroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−75−5 : 2−Nitrophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−75−5 : 2−Nitrophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−85−7 : Dinoseb

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 88−85−7 : Dinoseb

Agonist: 0 Antagonist: 0.00021

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−04−3 : Trioctyl trimellitate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−04−3 : Trioctyl trimellitate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−71−4 : Methyl 2−methylbenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−71−4 : Methyl 2−methylbenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−72−5 : 2−(Butan−2−yl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−72−5 : 2−(Butan−2−yl)phenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−78−1 : dl−Menthol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−78−1 : dl−Menthol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−83−8 : Thymol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−83−8 : Thymol

Agonist: 0.0072 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−87−2 : 1,3−Dimethyl−4−nitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 89−87−2 : 1,3−Dimethyl−4−nitrobenzene

Agonist: 0.0098 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−00−6 : 2−Ethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−00−6 : 2−Ethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−02−8 : Salicylaldehyde

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−02−8 : Salicylaldehyde

Agonist: 0.035 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9003−11−6 : Pluronic F−127

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9003−11−6 : Pluronic F−127

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−04−0 : 2−Anisidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−04−0 : 2−Anisidine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9004−82−4 : Sodium lauryl polyoxyethylene ether sulfate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9004−82−4 : Sodium lauryl polyoxyethylene ether sulfate

Agonist: 0.0051 Antagonist: 0.11

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9004−96−0 : Polyoxyethylene monoleate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9004−96−0 : Polyoxyethylene monoleate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−05−1 : 2−Methoxyphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−05−1 : 2−Methoxyphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9005−65−6 : Polysorbate 80

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9005−65−6 : Polysorbate 80

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−12−0 : 1−Methylnaphthalene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−12−0 : 1−Methylnaphthalene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−15−3 : 1−Naphthol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−15−3 : 1−Naphthol

Agonist: 0.033 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9016−00−6 : Polydimethylsiloxane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9016−00−6 : Polydimethylsiloxane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9016−87−9 : Isocyanic acid, polymethylenepolyphenylene ester

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 9016−87−9 : Isocyanic acid, polymethylenepolyphenylene ester

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−30−2 : N−Phenyl−1−naphthylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−30−2 : N−Phenyl−1−naphthylamine

Agonist: 0.031 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90357−06−5 : Bicalutamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90357−06−5 : Bicalutamide

Agonist: 0.0069 Antagonist: 0.13

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−43−7 : 2−Phenylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−43−7 : 2−Phenylphenol

Agonist: 0.015 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−72−2 : 2,4,6−Tris(dimethylaminomethyl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−72−2 : 2,4,6−Tris(dimethylaminomethyl)phenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90823−38−4 : Denatonium saccharide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90823−38−4 : Denatonium saccharide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−94−8 : Michler's ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 90−94−8 : Michler's ketone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91082−17−6 : C10−21 sulfonic acids phenyl esters

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91082−17−6 : C10−21 sulfonic acids phenyl esters

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−20−3 : Naphthalene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−20−3 : Naphthalene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−22−5 : Quinoline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−22−5 : Quinoline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91465−08−6 : lambda−Cyhalothrin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91465−08−6 : lambda−Cyhalothrin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−53−2 : Ethoxyquin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−53−2 : Ethoxyquin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−59−8 : 2−Naphthylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−59−8 : 2−Naphthylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−62−3 : 6−Methylquinoline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−62−3 : 6−Methylquinoline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−64−5 : Coumarin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−64−5 : Coumarin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−66−7 : N,N−Diethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 91−66−7 : N,N−Diethylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 919−30−2 : 3−Aminopropyltriethoxysilane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 919−30−2 : 3−Aminopropyltriethoxysilane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−04−6 : 2−Chloro−4−phenylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−04−6 : 2−Chloro−4−phenylphenol

Agonist: 0.16 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 924−16−3 : N−Nitrosodibutylamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 924−16−3 : N−Nitrosodibutylamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−52−4 : Biphenyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−52−4 : Biphenyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−68−2 : 4−Cyclohexylcyclohexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−68−2 : 4−Cyclohexylcyclohexanone

Agonist: 0.036 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−69−3 : 4−Phenylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−69−3 : 4−Phenylphenol

Agonist: 0.32 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−84−2 : Phenothiazine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−84−2 : Phenothiazine

Agonist: 0.01 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−87−5 : Benzidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 92−87−5 : Benzidine

Agonist: 0.013 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 928−96−1 : (Z)−3−Hexen−1−ol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 928−96−1 : (Z)−3−Hexen−1−ol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 929601−09−2 : SR58611

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 929601−09−2 : SR58611

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 930−55−2 : N−Nitrosopyrrolidine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 930−55−2 : N−Nitrosopyrrolidine

Agonist: 0.0024 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−08−3 : 2'−Acetonaphthone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−08−3 : 2'−Acetonaphthone

Agonist: 0.0049 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−15−2 : Methyleugenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−15−2 : Methyleugenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−56−1 : Styrene glycol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−56−1 : Styrene glycol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−65−2 : Mecoprop

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−65−2 : Mecoprop

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−76−5 : 2,4,5−Trichlorophenoxyacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−76−5 : 2,4,5−Trichlorophenoxyacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 938−16−9 : tert−Butyl phenyl ketone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 938−16−9 : tert−Butyl phenyl ketone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−89−0 : Ethyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−89−0 : Ethyl benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−92−5 : Benzenemethanol, alpha−methyl−, acetate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−92−5 : Benzenemethanol, alpha−methyl−, acetate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−99−2 : Phenyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 93−99−2 : Phenyl benzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−08−6 : Ethyl 4−methylbenzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−08−6 : Ethyl 4−methylbenzoate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−09−7 : Benzocaine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−09−7 : Benzocaine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−13−3 : Propylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−13−3 : Propylparaben

Agonist: 0.3 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 941−69−5 : 1−Phenyl−1H−pyrrole−2,5−dione

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 941−69−5 : 1−Phenyl−1H−pyrrole−2,5−dione

Agonist: 0 Antagonist: 0.02

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−18−8 : Benzylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−18−8 : Benzylparaben

Agonist: 0.35 Antagonist: 0.011

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−26−8 : Butylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−26−8 : Butylparaben

Agonist: 0.38 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−28−0 : Triethylene glycol bis(2−ethylhexanoate)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−28−0 : Triethylene glycol bis(2−ethylhexanoate)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94361−06−5 : Cyproconazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94361−06−5 : Cyproconazole

Agonist: 0.042 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−46−2 : Isopentyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−46−2 : Isopentyl benzoate

Agonist: 0.0038 Antagonist: 0.0087

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−47−3 : 2−Phenylethyl benzoate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−47−3 : 2−Phenylethyl benzoate

Agonist: 0.011 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−59−7 : Safrole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−59−7 : Safrole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−60−0 : Dimethyl hexahydroterephthalate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−60−0 : Dimethyl hexahydroterephthalate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−71−3 : 2−Ethoxyphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−71−3 : 2−Ethoxyphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−74−6 : MCPA

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−74−6 : MCPA

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−75−7 : 2,4−Dichlorophenoxyacetic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−75−7 : 2,4−Dichlorophenoxyacetic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−80−4 : 2,4−D 1−butyl ester

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−80−4 : 2,4−D 1−butyl ester

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−81−5 : MCPB

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−81−5 : MCPB

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−82−6 : 2,4−DB

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−82−6 : 2,4−DB

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−91−7 : N,N'−Disalicylidene−1,2−diaminopropane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−91−7 : N,N'−Disalicylidene−1,2−diaminopropane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−96−2 : 2−Ethyl−1,3−hexanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 94−96−2 : 2−Ethyl−1,3−hexanediol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 950−37−8 : Methidathion

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 950−37−8 : Methidathion

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−13−6 : Indene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−13−6 : Indene

Agonist: 0.0089 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−14−7 : 1,2,3−Benzotriazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−14−7 : 1,2,3−Benzotriazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−16−9 : Benzothiazole

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−16−9 : Benzothiazole

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95266−40−3 : Trinexapac−ethyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95266−40−3 : Trinexapac−ethyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−38−5 : 1H−Imidazole−1−ethanol, 2−(8−heptadecenyl)−4,5−dihydro−

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−38−5 : 1H−Imidazole−1−ethanol, 2−(8−heptadecenyl)−4,5−dihydro−

Agonist: 0.02 Antagonist: 0.03

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−48−7 : o−Cresol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−48−7 : o−Cresol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−49−8 : 2−Chlorotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−49−8 : 2−Chlorotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−50−1 : 1,2−Dichlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−50−1 : 1,2−Dichlorobenzene

Agonist: 0.0034 Antagonist: 0.0086

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−53−4 : 2−Methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−53−4 : 2−Methylaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−54−5 : 1,2−Phenylenediamine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−54−5 : 1,2−Phenylenediamine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−57−8 : 2−Chlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−57−8 : 2−Chlorophenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−63−6 : 1,2,4−Trimethylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−63−6 : 1,2,4−Trimethylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−65−8 : 3,4−Dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−65−8 : 3,4−Dimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95737−68−1 : Pyriproxyfen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95737−68−1 : Pyriproxyfen

Agonist: 0.022 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−74−9 : 3−Chloro−4−methylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−74−9 : 3−Chloro−4−methylaniline

Agonist: 0.0085 Antagonist: 0.021

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 957−51−7 : Diphenamid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 957−51−7 : Diphenamid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−76−1 : 3,4−Dichloroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−76−1 : 3,4−Dichloroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−80−7 : 2,4−Diaminotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−80−7 : 2,4−Diaminotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−83−0 : 4−Chloro−1,2−diaminobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−83−0 : 4−Chloro−1,2−diaminobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−87−4 : 2,5−Dimethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−87−4 : 2,5−Dimethylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−93−2 : 1,2,4,5−Tetramethylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−93−2 : 1,2,4,5−Tetramethylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−94−3 : 1,2,4,5−Tetrachlorobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−94−3 : 1,2,4,5−Tetrachlorobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−95−4 : 2,4,5−Trichlorophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 95−95−4 : 2,4,5−Trichlorophenol

Agonist: 0.017 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 959−98−8 : Endosulfan I

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 959−98−8 : Endosulfan I

Agonist: 0.092 Antagonist: 0.00026

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 960−71−4 : Triphenylborane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 960−71−4 : Triphenylborane

Agonist: 0.16 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−09−3 : Styrene oxide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−09−3 : Styrene oxide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96182−53−5 : Tebupirimfos

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96182−53−5 : Tebupirimfos

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−18−4 : 1,2,3−Trichloropropane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−18−4 : 1,2,3−Trichloropropane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−23−1 : 1,3−Dichloro−2−propanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−23−1 : 1,3−Dichloro−2−propanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−24−2 : 3−Chloro−1,2−propanediol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−24−2 : 3−Chloro−1,2−propanediol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 962−58−3 : Diazoxon

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 962−58−3 : Diazoxon

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−29−7 : 2−Butanone oxime

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−29−7 : 2−Butanone oxime

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−41−3 : Cyclopentanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−41−3 : Cyclopentanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−45−7 : Ethylene thiourea

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−45−7 : Ethylene thiourea

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−48−0 : 4−Butyrolactone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−48−0 : 4−Butyrolactone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96489−71−3 : Pyridaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96489−71−3 : Pyridaben

Agonist: 0.052 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−70−8 : 2−tert−Butyl−4−ethylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−70−8 : 2−tert−Butyl−4−ethylphenol

Agonist: 0.024 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−76−4 : 2,4−Di−tert−butylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−76−4 : 2,4−Di−tert−butylphenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−83−3 : Iopanoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 96−83−3 : Iopanoic acid

Agonist: 0.052 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−00−7 : 1−Chloro−2,4−dinitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−00−7 : 1−Chloro−2,4−dinitrobenzene

Agonist: 0 Antagonist: 0.047

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−23−4 : Dichlorophen

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−23−4 : Dichlorophen

Agonist: 0.017 Antagonist: 0.096

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97322−87−7 : Troglitazone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97322−87−7 : Troglitazone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−52−9 : 2−Methoxy−4−nitroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−52−9 : 2−Methoxy−4−nitroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−53−0 : Eugenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−53−0 : Eugenol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−54−1 : Isoeugenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−54−1 : Isoeugenol

Agonist: 0.017 Antagonist: 0.0013

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−56−3 : 2−Amino−5−azotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−56−3 : 2−Amino−5−azotoluene

Agonist: 0.21 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−59−6 : Allantoin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−59−6 : Allantoin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−77−8 : Disulfiram

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−77−8 : Disulfiram

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−78−9 : N−Dodecanoyl−N−methylglycine

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−78−9 : N−Dodecanoyl−N−methylglycine

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97886−45−8 : Dithiopyr

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97886−45−8 : Dithiopyr

Agonist: 0.046 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−99−4 : Tetrahydrofurfuryl alcohol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 97−99−4 : Tetrahydrofurfuryl alcohol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−00−0 : Furfuryl alcohol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−00−0 : Furfuryl alcohol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−01−1 : Furfural

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−01−1 : Furfural

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−06−6 : tert−Butylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−06−6 : tert−Butylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−07−7 : Benzotrichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−07−7 : Benzotrichloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98319−26−7 : Finasteride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98319−26−7 : Finasteride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−51−1 : 4−tert−Butyltoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−51−1 : 4−tert−Butyltoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−52−2 : 4−tert−Butylcyclohexanol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−52−2 : 4−tert−Butylcyclohexanol

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−53−3 : 4−tert−Butylcyclohexanone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−53−3 : 4−tert−Butylcyclohexanone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−54−4 : 4−tert−Butylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−54−4 : 4−tert−Butylphenol

Agonist: 0.22 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−56−6 : 1−Chloro−4−(trifluoromethyl)benzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−56−6 : 1−Chloro−4−(trifluoromethyl)benzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98730−04−2 : Benoxacor

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98730−04−2 : Benoxacor

Agonist: 0 Antagonist: 1e−04

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−86−2 : Acetophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−86−2 : Acetophenone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−87−3 : Benzal chloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−87−3 : Benzal chloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98886−44−3 : Fosthiazate

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98886−44−3 : Fosthiazate

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−92−0 : Niacinamide

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−92−0 : Niacinamide

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 989−38−8 : Rhodamine 6G

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 989−38−8 : Rhodamine 6G

Agonist: 0 Antagonist: 0.15

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−95−3 : Nitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98−95−3 : Nitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98967−40−9 : Flumetsulam

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 98967−40−9 : Flumetsulam

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−07−0 : 3−Dimethylaminophenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−07−0 : 3−Dimethylaminophenol

Agonist: 0.0058 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−08−1 : 3−Nitrotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−08−1 : 3−Nitrotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−30−9 : Dicloran

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−30−9 : Dicloran

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−51−4 : 1,2−Dimethyl−4−nitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−51−4 : 1,2−Dimethyl−4−nitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−54−7 : 3,4−Dichloronitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−54−7 : 3,4−Dichloronitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−55−8 : 2−Methyl−5−nitroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−55−8 : 2−Methyl−5−nitroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−59−2 : 2−Methoxy−5−nitroaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−59−2 : 2−Methoxy−5−nitroaniline

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99607−70−2 : Cloquintocet−mexyl

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99607−70−2 : Cloquintocet−mexyl

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−62−7 : 1,3−Diisopropylbenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−62−7 : 1,3−Diisopropylbenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−63−8 : 1,3−Benzenedicarbonyl dichloride

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−63−8 : 1,3−Benzenedicarbonyl dichloride

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−65−0 : 1,3−Dinitrobenzene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−65−0 : 1,3−Dinitrobenzene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−66−1 : Valproic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−66−1 : Valproic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−71−8 : 4−(Butan−2−yl)phenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−71−8 : 4−(Butan−2−yl)phenol

Agonist: 0.21 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−76−3 : Methylparaben

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−76−3 : Methylparaben

Agonist: 0.016 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−85−4 : gamma−Terpinene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−85−4 : gamma−Terpinene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−86−5 : alpha−Terpinene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−86−5 : alpha−Terpinene

Agonist: 0.029 Antagonist: 0.071

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−87−6 : p−Cymene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−87−6 : p−Cymene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−89−8 : 4−Isopropylphenol

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−89−8 : 4−Isopropylphenol

Agonist: 0.028 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−93−4 : 4−Hydroxyacetophenone

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−93−4 : 4−Hydroxyacetophenone

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−96−7 : 4−Hydroxybenzoic acid

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−96−7 : 4−Hydroxybenzoic acid

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−97−8 : N,N,4−Trimethylaniline

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−97−8 : N,N,4−Trimethylaniline

Agonist: 0.0054 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−99−0 : 4−Nitrotoluene

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 99−99−0 : 4−Nitrotoluene

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 999−97−3 : Hexamethyldisilazane

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 999−97−3 : Hexamethyldisilazane

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_34742 : Milbemectin (mixture of 70% Milbemcin A4, 30% Milbemycin A3)

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_34742 : Milbemectin (mixture of 70% Milbemcin A4, 30% Milbemycin A3)

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47248 : CI−1018

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47248 : CI−1018

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47255 : CP−465394

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47255 : CP−465394

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47265 : CP−471358

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47265 : CP−471358

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47267 : CP−642931

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47267 : CP−642931

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47291 : CI−1044

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47291 : CI−1044

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47292 : PD 0200347

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47292 : PD 0200347

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47299 : CP−422935

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47299 : CP−422935

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47305 : CP−608039

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47305 : CP−608039

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47311 : GSK163929B

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47311 : GSK163929B

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47325 : SB413217A

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47325 : SB413217A

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47328 : MK−274

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47328 : MK−274

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47330 : PharmaGSID_47330

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47330 : PharmaGSID_47330

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47333 : PharmaGSID_47333

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47333 : PharmaGSID_47333

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47334 : MK−968

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47334 : MK−968

Agonist: 0 Antagonist: 0.01

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47342 : SR125047

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47342 : SR125047

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47346 : SSR162369

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47346 : SSR162369

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47351 : SSR240612

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47351 : SSR240612

Agonist: 0.0047 Antagonist: 0.0059

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47353 : SSR241586

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47353 : SSR241586

Agonist: 0 Antagonist: 0.017

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47362 : SSR150106

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47362 : SSR150106

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47364 : SSR103800

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47364 : SSR103800

Agonist: 0 Antagonist: 0.015

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47366 : SAR115740

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47366 : SAR115740

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47374 : SSR161421

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47374 : SSR161421

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47377 : AVE6324

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47377 : AVE6324

Agonist: 0.012 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47379 : SSR126768

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47379 : SSR126768

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47383 : AVE3247

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47383 : AVE3247

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47385 : SAR377142

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47385 : SAR377142

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47387 : SAR102779

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47387 : SAR102779

Agonist: 0 Antagonist: 0.0097

Concentration (uM)Receptor Score1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47389 : SAR150640

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47389 : SAR150640

Agonist: 0 Antagonist: 0.0036

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47708 : Igepal CO−890

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47708 : Igepal CO−890

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47796 : Formalin

Concentration (uM)Efficacy − fraction(E2)

1e−02 1e−01 1e+00 1e+01 1e+020.00.20.40.60.81.0 NOCAS_47796 : Formalin

Agonist: 0 Antagonist: 0

Concentration (uM)Receptor Score